 
               [STUDY_ID_REMOVED] 
 
Study ID:  1789-202-008 
 
 
Title: BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle 
Prominence: A Phase 2b, Multicenter, Randomized, Double -Blind, Multi -
Dose, Placebo- Controlled Study  
 
                             Protocol Date: February 12, 2019  
 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Title Page 
Protocol Title: BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: 
A Phase 2b, Multicenter, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study 
Protocol Number: 1789-202-008  
Product: OnabotulinumtoxinA Brief Protocol Title: BOTOX Treatm ent of Masseter Muscle Prominence  
Development Phase: 2b 
Sponsor Name and Legal Registered Address:  
Allergan Sales LLC  
5 Giralda Farms Madison, NJ 07940 
USA 
Regulatory Agency Identifying Number: IND 133,035 
Emergency Telephone Number   Refer to the study contacts page  
SAE Reporting Fax Number/Email:   
Business Unit  Email Phone Fax 
Allergan  Not applicable  
 
Sponsor Signatory: 
  
Associate Vice President and Section Head 
Medical Aesthetics  
Refer to the final page of this protocol fo r electronic signature and date of approval. 
 
11DEC2020 CSR 1789-202-008
1

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Table of Contents 
Title Page ........................................................................................................................................1  
Table of Contents ...........................................................................................................................2  
List of Tables ..................................................................................................................................5  
List of Figures ............................................................................................................... ..................5  
1. Protocol Summary ..........................................................................................................6  
1.1. Synopsis ...................................................................................................................... ......6  
1.2. Schema ........................................................................................................................ ......9  
1.3.  
2. Introduction .................................................................................................................. .13 
2.1. Study Rationale ............................................................................................................... 13 
2.2. Background .................................................................................................................... .14 
2.3. Benefit/Risk Assessment ................................................................................................15  
3. Objectives and Endpoints ............................................................................................17  
4. Study Design .................................................................................................................. 18 
4.1. Overall Design ................................................................................................................ 18 
4.2. Scientific Rationale for Study Design ............................................................................18  
4.3. Justification for Dose ......................................................................................................20  
4.4. End of Study Definition ..................................................................................................21  
5. Study Population ...........................................................................................................22  
5.1. Inclusion Criteria ............................................................................................................ 22 
5.2. Exclusion Criteria ...........................................................................................................2 3 
5.3. Lifestyle Considerations .................................................................................................25  
5.4. Screen Failures ............................................................................................................... .25 
6. Study Intervention ........................................................................................................26  
6.1. Study Interventions Administered ..................................................................................26  
6.1.1.  Other Study Supplies ......................................................................................................29  
6.2. Preparation/Handling/Storage/Accountability ................................................................29  
6.3. Measures to Minimize Bias: Randomization and Blinding ............................................30  
6.4. Study Intervention Compliance ......................................................................................31  
6.5. Concomitant Therapy .....................................................................................................31  
6.5.1.   
6.5.2.   
6.5.3.   
6.6. Dose Modification ..........................................................................................................33  
6.7. Intervention After the End of the Study ..........................................................................33  
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal........................................................................................33  
11DEC2020 CSR 1789-202-008
2

Approval Date : 12-Feb-2019Protocol 1789-202-008
BOTOX 
 
7.1. Discontinuation of Study Intervention ............................................................................34  
7.2. Participant Discontinuation/W ithdrawal from the Study ................................................34  
7.3. Lost to Follow Up ...........................................................................................................34  
8. Study Assessments and Procedures.............................................................................36  
8.1. Efficacy Assessments .....................................................................................................36  
8.1.1.  Primary Efficacy Assessment .........................................................................................36  
8.1.2.  Secondary Efficacy Assessments ....................................................................................37  
8.1.3.  Other/Exploratory Efficacy Assessments .......................................................................38  
8.1.4.  Additional Assessments ..................................................................................................39  
8.2. Safety Assessments .........................................................................................................40  
8.2.1.  Vital Signs ................................................................................................................... ....40  
8.2.2.  Height and Weight ..........................................................................................................40  
8.2.3.  Pregnancy Testing ...........................................................................................................40  
8.2.4.  Oral Examination ............................................................................................................40  
8.2.5.  Screening for TMJD .......................................................................................................41  
8.3. Adverse Events and Serious Adverse Events .................................................................41  
8.3.1.  Time Period and Frequency for Collecting Adverse Event an d 
Serious Adverse Event Information ................................................................................41  
8.3.2.  Method of Detecting Adverse Events and Serious Adverse 
Events ........................................................................................................................ ......42  
8.3.3.  Follow-up of Adverse Events and Serious Adverse Events ...........................................42  
8.3.4.  Regulatory Reporting Requirements fo r Serious Adverse Events ..................................42  
8.3.5.  Pregnancy ..................................................................................................................... ...43  
8.3.6.  Protocol-Specific Adverse Events ..................................................................................43  
8.3.7.  Adverse Events of Special Interest .................................................................................43  
8.3.8.  Medication Errors ...........................................................................................................43  
8.4. Treatment of Overdose ...................................................................................................44  
8.5. Pharmacokinetics ............................................................................................................44  
8.6. Pharmacodynamics .........................................................................................................44  
8.7. Genetics ..........................................................................................................................44  
8.8. Biomarkers and Other Assessments ...............................................................................44  
8.9. Health Economics ...........................................................................................................44  
9. Statistical Considerations .............................................................................................45  
9.1. Statistical Hypotheses .....................................................................................................45  
9.2. Sample Size Determination ............................................................................................45  
9.3. Populations for Analyses ................................................................................................45  
9.4. Statistical Analyses .........................................................................................................4 5 
9.4.1.  Efficacy Analyses ...........................................................................................................46  
9.4.2.  Safety Analyses ...............................................................................................................47  
9.4.3.  Other Analyses ................................................................................................................ 48 
9.5. Interim Analyses .............................................................................................................48  
10. Supporting Documentation and Operational Considerations ..................................49  
11DEC2020 CSR 1789-202-008
3

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ................................................................................................................ 49 
10.1.1.  Regulatory and Ethical Considerations ...........................................................................49  
10.1.2.  Financial Disclosure ........................................................................................................49  
10.1.3.  Informed Consent Process ..............................................................................................50  
10.1.4.  Data Protection................................................................................................................ 50 
10.1.5.  Posting Clinical Study Data ............................................................................................50  
10.1.6.  Data Quality Assurance ..................................................................................................50  
10.1.7.  Source Documents ..........................................................................................................51  
10.1.8.  Study and Site Closure ....................................................................................................51  
10.1.9.  Publication Policy ...........................................................................................................5 2 
10.1.10.  Compliance with Protocol...............................................................................................52  
10.2.  Appendix 2: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting .........................................................53
 
10.3.  Appendix 3: Abbreviations .............................................................................................58  
10.4.  Appendix 4: Standard Discontinuation Criteria..............................................................60  
10.5.  Appendix 5: Study Tabular Summary ............................................................................62  
10.6.  Appendix 6: Contraceptive Guidance and Collection of Pregnancy Information ...................................................................................................64
 
10.7.  Appendix 7: Efficacy Measures ......................................................................................67  
10.7.1.  Masseter Muscle Prominence Scale – Investigator Assessment .....................................67  
10.7.2.  Lower Facial Volume Measurement ...............................................................................69  
10.7.3.  Facial Width Measurement .............................................................................................70  
10.7.4.  Mandibular Facial Angle Measurement ..........................................................................72  
10.8.  Appendix 8: Example Patient Reported Outcomes Questionnaires, Descriptions, and Instructions...............................................................73
 
10.8.1.  Masseter Muscle Prominence Scal e – Participant (MMPS-P) .......................................73  
10.8.2.  Masseter Muscle Prominence Participant Self-Assessment of Change (PSAC) ...............................................................................................................75
 
  
  
  
  
  
  
  
 
11. References .................................................................................................................... ..88 
 
11DEC2020 CSR 1789-202-008
4

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
List of Tables 
Table 1–1  Schedule of Visits and Procedures .................................................................... 11  
Table 6–1  Study Interventions Administered ..................................................................... 26  
Table 6–2  Injection Volume ............................................................................................... 29 
Table 10-1  Highly Effective and Acceptable Contraceptive Methods ................................ 65  
 
List of Figures 
Figure 1-1  Study Schema ...................................................................................................... 9  
Figure 6-1  Schematic of Injection Area .............................................................................. 28  
Figure 10-1  Lower Facial Volume Measurement ................................................................. 69  
Figure 10-2  Standardized Target AOI from a 3D Facial Shape Model ................................ 70  
Figure 10-3  Lower Facial Widt h Measurement .................................................................... 71  
Figure 10-4  Mandibular Facial Angle Measurement ............................................................ 72  
 
11DEC2020 CSR 1789-202-008
5

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
1. Protocol Summary 
1.1. Synopsis 
Protocol Title: BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: 
A Phase 2b, Multicenter, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study 
Protocol Number:  1789-202-008 
Brief Title:  BOTOX Treatment of Masseter Muscle Prominence 
Study Phase : 2b 
Study Rationale:  
The masseter muscle is 1 of 4 muscles used for mastication. Prominence of the masseter muscle 
can appear as a widened lower face, which is an  aesthetic concern for in dividuals who prefer a 
narrower lower face shape. When BOTOX is inj ected into a masseter muscle, BOTOX treatment 
has been observed to reduce the size of the muscle ( Moore 1994 ), producing an effect perceived 
as lower facial shaping or slimmi ng (Wu 2010). 
Study 191622-130 was the first Allergan-sponsored  study of BOTOX for the treatment of 
masseter muscle prominence (MMP). This was a 12-month, multicenter, double-blind, 
randomized, placebo-controlled, dose-escalation, Phase 2 study in which BOTOX treatment of 
MMP was shown to be safe at doses ra nging from 24 U (12 U/masseter) to 96 U 
(48 U/masseter). Participants were ad ults < 50 years with body mass index ≤ 30 kg/m2 and who 
had marked to very marked  MMP, assessed by the investigat or using the Masseter Muscle 
Prominence Scale (MMPS). For the primary and key secondary endpoints (at Day 90), 
statistically significant positive efficacy results were demonstrated for all 4 BOTOX doses, with 
a dose-dependent trend favoring the higher 3 doses (48 U, 72 U, and 96 U), which produced 
statistically significant changes in MMP compared with placebo. There were no safety trends or 
patterns identified with a dose incr ease, although facial paresis (i ncluding reports of weak or 
altered smile) was reported in the highest  dose group (96 U) as a local effect.  
Based on the results of the Phase 2 Study 191622-130, the current Phase 2b study is designed to 
further evaluate the safety and efficacy of BOTOX 48 U and 72 U for th e treatment of MMP in 
adults. 
11DEC2020 CSR 1789-202-008
6

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Objectives and Endpoints: 
Objectives Endpoints 
Primary  
 To compare the efficacy of 
BOTOX with placebo in 
participants with bilateral 
MMP   Proportion of responders who achieve MMPS Grade ≤ 3 at Day 90, per 
investigator assessments of MMP using the MMPS (5 severity grades: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked, 5 = very marked) 
 To compare the safety of BOTOX with placebo in participants with MMP  Incidence of adverse events (AEs) and change from baseline in vital signs 
Secondary  
 To compare the efficacy of 
BOTOX with placebo in 
participants with MMP based on multiple clinical 
efficacy assessments   Proportion of responders who achieve  Masseter Muscle Prominence Scale – 
Participant (MMPS-P) Grade ≤ 3 at Day 90, per participant assessments of 
MMP using the MMPS-P (5 severity grades: 1 = not at all pronounced, 2 = mildly pronounced, 3 = moderately pronounced, 4 = pronounced, 
5 = very pronounced) 
 Proportion of responders who achieve ≥ 2-grade improvement from 
baseline at Day 90, per investigator using the MMPS  
 Proportion of responders who achieve ≥ 2-grade improvement from 
baseline at Day 90, per participant using the MMPS-P 
 Proportion of responders who achieve Participant Self-Assessment of Change (PSAC) Grade ≥ 2 (at least moderately improved from baseline) at 
Day 90, per participant using the PSAC 
 Change from baseline in lower facial volume (cm
3) at Day 90, calculated 
from standardized images 
  
  
 
 
  
  
  
 
  
 
  
 
 
  
 
  
 
 
  
 
 
 
11DEC2020 CSR 1789-202-008
7

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Overall Study Design: 
This is a 6-month, multicenter study consisting of a single treatment period. The study is a 
double-blind, randomized, placebo-controlled, single-treatment design, which will assess the 
safety and efficacy of BOTOX treatment for MM P. Up to 8 scheduled visits are planned: 
screening (Day -14 to Day -1), baseline (Day 1), follow-up (Days 30, 60, 90, 120, 150), and study exit (Day 180). 
Number of Participants: 
Approximately 150 participants will be randomized  in a 1:1:1 ratio yielding approximately 
50 participants in each of the BOTOX 48 U and 72 U groups and 50 in the placebo group.  
Number of Sites: 
Approximately 15 sites in the US 
Intervention Groups and Study Duration: 
On Day 1, participants will be randomized in a 1:1:1 ratio to receive a single treatment of 
BOTOX 48 U, BOTOX 72 U, or placebo. Randomization will be stratified at each investigator 
site by the participant’s baseline MMPS Grade (4 or 5). After verification that the participants 
meet all inclusion and exclusion criteria and completion of all baseline study procedures, 
participants will be randomized and enrolled.  
Treatments will be administered intramuscularly to the bilateral masseter muscles as  
 
The total study duration is approximately 6 months. 
Data Monitoring Committee: No 
11DEC2020 CSR 1789-202-008
8

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
11DEC2020 CSR 1789-202-008
9

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
11DEC2020 CSR 1789-202-008
10

 
 
 
 
Approval  Date:  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
11DEC2020 CSR 1789-202-008
11

 
 
 
 
Approval  Date:  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 
 
11DEC2020 CSR 1789-202-008
12

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
2. Introduction 
BOTOX has been used for therapeutic and aesth etic purposes for 3 decades, with its first 
therapeutic approval (treatment of facial spasmodic disorder s) in 1989 and first aesthetic 
approval (treatment of glabellar lines) in 2002. Since the first reports of clinical results with 
botulinum toxin type A treatment of MMH ( Moore 1994, Smyth 1994), nu merous publications 
in the medical literature s uggest BOTOX may be a locally applied, well-tolerated, and 
predictable treatment to improve the appearan ce of the masseter muscles in the lower face. 
Compared with conservative approaches, BOTOX may produce a relatively rapid, predictable, 
and desired effect of reducing the size and shape of the masse ter muscles; compared with 
surgical treatment, BOTOX injections may be less invasive, may lead to fewer side effects and a 
shorter recovery time, and the chemical denervation of the masseter muscle is temporary. 
2.1. Study Rationale 
The masseter muscle is 1 of 4 muscles used for mastication. Prominence of the masseter muscle 
can appear as a widened and square lower f ace shape, which is an aesthetic concern for 
individuals who prefer a narrower an d more ovoid lower face shape.  
When BOTOX is injected into a muscle, it interferes with neuromuscular transmission, 
producing temporary chemical dene rvation resulting in localized relaxation of the muscle and 
reduction in muscle activity. When injected into  a masseter muscle, BOTOX treatment has been 
observed to reduce the size of the muscle (Moore 1994), producing an effect perceived as lower 
facial shaping or slimmi ng (Wu 2010 ). 
Study 191622-130 was the first Allergan-sponsored study of BOTOX for the treatment of MMP 
as an aesthetic indication. This was a 12-m onth, multicenter, double-blind, randomized, placebo-
controlled, dose-escalation, Phase 2 study in wh ich BOTOX treatment of MMP was shown to be 
safe at doses ranging from 24 U (12 U/masseter) to 96 U (48 U/ masseter). Participants were 
adults < 50 years with BMI ≤ 30 kg/m2 and who had marked  to very marked  MMP, assessed by 
the investigator using the MMPS. For the prim ary and key secondary endpoints (at Day 90), 
statistically significant positive efficacy results  were demonstrated for all 4 BOTOX doses 
compared with placebo, with a dose-dependent trend favoring the higher 3 doses (48 U, 72 U, 
and 96 U). There were no safety trends or patterns identified with a dose increase, although facial 
paresis (including reports of weak or altered sm ile) was reported in the highest dose group (96 U) 
as a local effect. For details of dose selection a nd justification for the cu rrent Phase 2b study, see 
Section 4.3. 
Study 191622-130 safety measures included standardiz ed dental and CT exams with the goal to 
identify and characterize BOTOX treatment effects on dentition,  masseter muscle volume, and 
11DEC2020 CSR 1789-202-008
13

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
the mandible. Dental exam data yielded no a bnormal clinically meaningful posttreatment 
findings for any participant in the study. No safety signal or unexpect ed new pathological 
development was detected from any exploratory radiologic CT measure. There were no dose-
related trends, AE reports, or abnormal clinical ly relevant findings on dental examination. 
Based on the results of the Phase 2 Study 191622-130, the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX 48 U and 72 U for th e treatment of MMP in 
adults.  
2.2. Background 
The masseter muscle functions to protract and elevate the mandible for mastication. Prominence 
of the masseter muscle can appear as a widened lower face, which is an aesthetic concern for 
individuals who prefer a narrower lower face shape. Individuals who deem this masseter 
prominence as aesthetically undesirable may seek medical treatment to decrease a wide, bulky, 
or square-appearing lower face (Ahn 2004, Chai 2011, Jin 2005, Klein 2014, Liew 2008, Morris 2007, Mu 2010, Pu 2009, Shim 2010 ). 
In medical literature, MMH can be defined as encompassing both functional and aesthetic 
symptoms of an enlarged masseter muscle ( Fedorowicz 2013). Allerg an’s focus is the aesthetic 
indication; to clarify this, Allergan has sh ifted from the term MMH used in Study 191622-130 to 
the term MMP for the remainde r of the development program. 
MMP may be unilateral or bilateral. It may be idiopathic or may occur in association with 
conditions such as bruxism, occlusal and muscular imbalances, TMJD, or particular chewing habits and/or diets (eg, unilateral ch ewing, chewing gum  or hard foods) ( Aydil 2012, Choe 2005, 
Mischkowski 2005 ). The highest incidence of MMP is beli eved to occur in the second and third 
decades of life, and there is no gender predilectio n (Smyth 19 94). Patients with MMP may also 
have mandibular bony prominence (eg, a prominent mandibular angle) that may contribute to the 
appearance of a wide lower face.  
BOTOX has been used to treat MMP in clinical  practice for over 2 decades, predominantly in 
Asian countries where aesthetics favor a slender ovoid facial shape (Ahn 2004, Chang 2016, 
Liew 2008, Moore 1994 ). There is growing interest in MMP treatm ent among non-Asian 
populations (Liew 2008) and published reports char acterize the patient p opulation (Asian and 
non-Asian), injection technique s utilized, clinical result s achieved, and AEs (Ahn 2004, 
Aydil 2012, Choe 2005, Liew 2008, Peng 2017). As a potentially lower-risk alternative to 
surgical intervention, the aesthetic procedure of treating the masseter muscle with botulinum 
toxin has gained popularity among physicians and patients (Ahn 2004, Xie 2014 ). 
11DEC2020 CSR 1789-202-008
14

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
2.3. Benefit/Risk Assessment 
Current treatment options for MMP include cons ervative (nonsurgical) as well as invasive 
treatment modalities. Conservative treatments include reducing the muscular function and 
activity by behavioral modification, occlus al splints, and/or muscle relaxants ( Ahn 2004, 
Aydil 2012, Mischkowski 2005, Rauso 2010, Tartaro 2008, To 2001 ). These m ethods have not 
been rigorously studied for this indication and are believed to have limited efficacy. Invasive 
therapies for treating a wide lower face includ e surgical procedures such as osteotomy, 
ostectomy, and corticectomy to change the shap e of the jawline targeting the mandible and/or 
including excision of the masseter ( Baek 1989, Chai 2011, Deguchi 1997, Jin 2004, Jin 2005, 
Kim 2001, Kim 2003, Lee 2003, Lee 2006, Mu 2010, Onizuka 1983, Sumiya 2004, Yang 1991 ), 
and radiofrequency volumetric reduction of the masseter ( Park 2007). Risks of surgical reduction 
of the mandible and/or masseter muscle include  those of a general anesthetic, pain and 
discomfort, postoperative hemorrhage, edema, he matoma, infection, scarring, injury to the 
alveolar nerve, fracture of the ramus, c ondyle, or subcondyle mandibular bone structures, 
asymmetric result, and facial nerve damage (Baek 1989, Chai 2011, Choe 2005, Deguchi 1997, 
Jin 2005, Morris 2007, Mu 2010, Pu 2009, Yang 1995 ). BOTOX for MMP repres ents a 
potentially lower-risk alternative to surgical in tervention and higher efficacious alternative to 
other conservative nonsurg ical treatment options. 
In general, data from the completed Phase 2 clinical study of BOTOX treatment of MMP and 
from the medical literature show that BOTOX treatment of MMP has been well tolerated with 
AEs that were primarily local and expected, ba sed on the well-established safety profile of 
BOTOX and the muscles injected. In the Phase 2 Study 191622-130, the most frequently 
reported treatment-related AEs included co mmonly occurring conditions in the general 
population (eg, headache [2.0%, 3/150]), events a ssociated with the injection procedure (eg, 
injection site pain [3.3%, 5/150]), or events re lated to local muscle weakness that impact smiling 
or chewing that are consistent with th e known BOTOX pharmacological effects following 
injection into the masseter (eg, mastication diso rder [5.3%, 8/150] and facial paresis [2.7%, 
4/150; reported verbatim terms: weakness when smiling, altered smile, right depressor labia inferior paresis, and participant-noticed possible loss of movement along jawline]).  
Similar safety results have been described in the medical literature fo llowing BOTOX treatment 
of MMP in 1178 participants with various dos es (ranging from 10 to 100 U/masseter) and 
numbers of treatment cycles (Section 5.2.2 of  the Masseter Muscle Prominence Investigator 
Brochure). The most frequently reported AEs were pain, discomfort, or muscle ache at the sites 
of injection. Because the massete r muscle is one of the primary muscles of mastication, its 
treatment resulted in some reports of transi ent masticatory difficulties (weakness chewing), 
which was the next most frequently reported AE in these publications. BOTOX injection of the masseter and/or adjacent facial muscles also resulted in some cosmetic complaints, which were 
11DEC2020 CSR 1789-202-008
15

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
reported less frequently. In gene ral, adverse reactions occur within the first few days to weeks 
following injection of BOTOX and, while generally transient, ma y have a duration of several 
months or, in rare cases, longer. More detailed information about the known and expected 
benefits and risks and reasonably expected AE s with BOTOX treatment may be found in the 
investigator’s brochure and package insert. 
11DEC2020 CSR 1789-202-008
16

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
3. Objectives and Endpoints 
Objectives Endpoints 
Primary  
 To compare the efficacy of 
BOTOX with placebo in 
participants with bilateral MMP   Proportion of responders who achieve MMPS Grade ≤ 3 at Day 90, per 
investigator assessments of MMP using the MMPS (5 severity grades: 
1 = minimal, 2 = mild, 3 = moderate, 4 = marked, 5 = very marked) 
 To compare the safety of BOTOX with placebo in 
participants with MMP  Incidence of AEs and change from baseline in vital signs 
Secondary  
 To compare the efficacy of 
BOTOX with placebo in participants with MMP based on multiple clinical efficacy 
assessments   Proportion of responders who achieve MMPS-P Grade ≤ 3 at Day 90, per 
participant assessments of MMP using the MMPS-P (5 severity grades: 
1 = not at all pronounced, 2 = mildly pronounced, 3 = moderately 
pronounced, 4 = pronounced, 5 = very pronounced) 
 Proportion of responders who achieve ≥ 2-grade improvement from 
baseline at Day 90, per investigator using the MMPS  
 Proportion of responders who achieve ≥ 2-grade improvement from 
baseline at Day 90, per participant using the MMPS-P 
 Proportion of responders who achieve PSAC Grade ≥ 2 (at least 
moderately improved from baseline), per participant using the PSAC 
 Change from baseline in lower facial volume (cm3) at Day 90, calculated 
from standardized images 
  
 
 
  
 
 
 
 
 
 
 
 
11DEC2020 CSR 1789-202-008
17

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
4. Study Design 
4.1. Overall Design 
This is a 6-month, multicenter study consisting of a single treatment period and approximately 
150 enrolled participants. The study is a double-blind, randomized, placebo-controlled, 
single-study-intervention design, which will assess the safety and efficacy of BOTOX treatment 
for MMP (see Schema, Section 1.2). 
On Day 1, participants will be randomized in a 1:1:1 ratio to receive a single treatment of 
BOTOX 48 U, BOTOX 72 U, or placebo. Randomization will be stratified at each investigator 
site by the participant’s baseline MMPS Grade (4 or 5). Up to 8 schedule d visits are planned: 
screening (Day -14 to Day -1), baseline (Day 1), follow-up (Days 30, 60, 90, 120, 150), and study exit (Day 180). 
After verification that the participants meet all inclusion and exclusion cr iteria and completion of 
all baseline study procedures, participants wi ll be randomized and enrolled. Once enrolled, 
participants will spend approxima tely 6 months in the study.  
On Day 1, participants will r eceive a single treatment of either BOTOX (48 U or 72 U) or 
placebo administered bilaterally to the masseter muscles as 3 injections/masseter in the area of 
maximal muscle bulge  (Figure 6-1 , Section 6.1). The final reconstituted volume for all 
interventions will be the same 1.8 mL (0.3 mL per injection site). This is to ensure the 
investigator and participant rema in blinded to the study intervention administered. An IDR, who 
has no other participant-related ac tivities for this study, will prep are all study interventions. After 
study intervention is administered on Day 1, par ticipants will return for follow-up assessments 
(  
4.2. Scientific Rationale for Study Design 
In the current study, all participants will be assessed for a minimum of 180 days after double-
blind study intervention on Day 1. A randomized double-blind design minimizes investigator and 
participant bias and the placebo control provide s a comparator. Previous studies, including 
Allergan’s Study 191622-130, reported peak efficacy  of botulinum toxin treatment of MMP at 
3 months ( Hong 2005, Kim 2003, Kim 2007, Park 2003 ), therefore, Day 90 has been chosen as 
the primary timepoint in the present study. In Study 191622-130, statistically  significant effects 
were lost for most efficacy measures after 6 mont hs; therefore, a follow-up period of 180 days is 
considered appropriate for this Phase 2b study. 
11DEC2020 CSR 1789-202-008
18

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Allergan developed the MMPS, a clinician’s assessment tool for evaluation of MMP. In the 
present study, the MMPS is to be used by trained clinicians to evaluate and grade the prominence 
of the masseter muscle on the left and right side s of the face as the primary endpoint measure. 
The MMPS is a static measurement encompassing both visual and palpable examination of the 
masseter muscle at rest and at jaw-clench state. The MMPS showed substantial inter- and intra-
rater reliability in the no ntreatment scale validation Study 191622-128, confirming its 
acceptability for use in the present study. Study 191622-130 was the first study to use the MMPS to assess the treatment effect of BOTOX and it demonstrated statistica lly significant greater 
proportions of responders in achieving both a MMPS Grade ≤ 3, and ≥ 1-grade or ≥  2-grade 
improvements from baseline, as assessed by the i nvestigator at the primary timepoint. Results 
from Study 191622-130 support a clinician tool (MMPS) that can immediately assess the 
relevant masseter prominence without requiring radiological exposure from CT scans or 3D 
standardized imaging that requires a trained photo analyst to confirm the aesthetic complaint 
described by the participant.  
In the medical literature, various  imaging methods have been used to assess effects of botulinum 
toxin on masseter muscle size and lower facial sh ape (refer to the investigator’s brochure). 
Technologies used to measure quantitative changes in masseter muscle volume have included 
ultrasound, CT, and MRI. Photographic technolog ies developed to provide 3D quantitative 
analysis of facial morphology include image subtraction technique, moire topography, liquid crystal scanning, light luminance scanning, la ser scanning, stereo-lithography, and passive 
stereophotogramme try (Adriaens 2012, Kim 200 5, Tzou 2011), which all measure change to the 
lower facial contour.  
The VECTRA M3 3D Stereophotogrammetry system (Canfield Scientific, Inc.; Fairfield, New 
Jersey, USA) will be used to quantify the effect of BOTOX on lower facial volume as a 
secondary endpoint measure. This system has prev iously been validated for use in the facial 
region ( de Menezes 20 10), and the lower facial area encompassing the masseter muscle (MV 
Report#1832, MV-Report#1832-Addendum). The efficacy measures used to quantitate volume 
in Study 191622-130 demonstrated that lower fa cial volume reductions using 3D images 
(primary endpoint) correlated well with volume reductions in masseter muscle in a defined 
region using CT scans. Similarly, decreases in lower facial width using 2D image projections 
showed improvements comparable with  the 3D and CT volume results.  
 
 
 
 
11DEC2020 CSR 1789-202-008
19

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Safety assessments include AEs and vital signs. In the Phase 2 Study 191622-130, the most 
frequently reported AEs included commonly-occurring conditions in the ge neral population (eg, 
nasopharyngitis [8.0% of all BOTOX-treated part icipants], upper respiratory tract infection 
[6.0%], and headache [5.3%]) or events related to chewing that are not unexpected following 
injection into the masseter (eg, mastication di sorder [6.0%]). Of the reported AEs among the 
1178 subjects treated with BOTOX for MMP in the published medical literature, the most 
frequently reported AEs were pain, discomfort, or muscle ache at the sites of injection. Because 
the masseter muscle is one of the primary muscles of mastication, its treatment resulted in some 
reports of transient masticatory difficulties (ie, weakness chewing), which was the next most 
frequently reported AE in these publications. BO TOX injection of the masseter and/or adjacent 
facial muscles also resulted in some cosmetic complaints, which were reported less frequently. In 
general, these AEs have been reported as  mild and resolved without treatment.  
Study 191622-130 yielded no new or meaningful safety findings from dental or CT exams, rather 
analysis of AEs provided the most sensitive assessment of safety ; thus, this Phase 2b study uses 
routine AE monitoring (as well as vital sign monitoring) to characterize safety. 
4.3. Justification for Dose 
In Allergan’s Phase 2 Study 191622-130, particip ants received total doses ranging from BOTOX 
24 U to 96 U. For the primary and key secondary  endpoints (at Day 90), st atistically significant 
positive efficacy results were demonstrated for all 4 BOTOX doses, with a dose-dependent trend 
favoring the higher 3 doses (48 U, 72 U, and 96 U), which produced statistically significant 
changes in MMP compared with placebo. The benefits of 72 U and 96 U were similar for 
duration (approximately 9 months for Kaplan-M eier median time to loss of 1-grade MMPS 
response), volume reduction, MMPS Grade change, faci al width, facial angl e, and facial shape. 
There was no additional benefit demonstrated with 96 U over 72 U. Statistically significant 
efficacy results were also obtained with the 24 U dose versus placebo for the majority of 
endpoints evaluated, though not al l. However, the Kaplan-Meier duration of effect based on 
median time to loss of MMPS 1- or 2-grade improvement was approximately 3 to 7 weeks 
shorter in the BOTOX 24 U group than the BOTOX 48 U group.  
The proportion of responders achieving a rating of ≤ 3 (moderate) on the MMPS was 
significantly greater with all BO TOX doses compared with placebo (p < 0.008), with the greatest 
impact shown in the 48 U (83.3%), 72 U (89.5% ), and 96 U (89.5%) dose groups at Day 90.  
Participants treated with BOTOX experienced si gnificant reductions in lower facial volume 
(cm3) at Day 90 compared with placebo (p < 0.001), with the greatest mean  reductions shown in 
the 3 highest BOTOX dose groups of 48 U (-6.84 cm3), 72 U (-7.41 cm3), and 96 U (-8.20 cm3).  
11DEC2020 CSR 1789-202-008
20

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
The responder rate for achieving a 2-grade improvement from baseline using the MMPS was 
significantly greater with all BO TOX doses compared with placebo (p < 0.001), with the greatest 
proportion of responders in the 72 U (73.7%) an d the 96 U (65.8%) dose groups at Day 90; the 
proportion of responders in the 48 U dose group was 47.2%. 
BOTOX administration was shown to be safe th rough Day 360 for all doses (24 U, 48 U, 72 U, 
and 96 U). Facial paresis (including reports of w eak or altered smile) was reported in the highest 
dose group (96 U) as a local effect. 
A review of the medical literature of BO TOX treatment of MMH found a mean dose of 
approximately 38 U per masseter (range: 10 U to 100 U/masseter) administered into 1 to 6 
injection sites/masseter (refer to the investigator ’s brochure). This compares with doses of 24 U 
to 36 U per masseter to be used in this study. 
Based on efficacy and safety data obtained in the Phase 2 Study 191622-130, including duration 
of effect, and taking into  account data available in the medical literature, this study will evaluate 
total doses of 48 U and 72 U BOTOX versus placebo. 
4.4. End of Study Definition 
The end of the study is defined as the date of the last visit of the last participant. 
A participant is considered to have completed th e study if he/she is a randomized participant who 
was treated with study interv ention, has not been discont inued for any reason, and 
attends/completes the study exit visit. 
11DEC2020 CSR 1789-202-008
21

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
5. Study Population 
The study population will be adult participants with marked  (Grade 4) or very marked  (Grade 5) 
MMP as determined by the inves tigator using the MMPS AND with pronounced  (Grade 4) or 
very pronounced  (Grade 5) MMP as determined by the participant using the MMPS-P; and who 
meet eligibility criteria for this protocol as specified in Sectio n 5.1 and Section 5.2. 
Prospective approval of protocol deviations to recruitment and en rollment criteria, also known as 
protocol waivers or exemptions, are not permitted. 
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
1. Age 
1.01 Participant must be at least 18 years of age (or older if legal age of adulthood is > 18 
as per local regulations), at the time of signing the informed consent  
2. Type of Participant and Masseter Characteristics 
2.01  
2.02 Participant has a marked (Grade 4) or very marked (Grade 5) bilateral MMP 
(identical grades for left and right masseter), as determined at the Day 1 visit by the 
investigator using the MMPS 
2.03 Participant has a pronounced (Grade 4) or  very pronounced (Grade 5) MMP, as 
determined at the Day 1 visit by the participant using the MMPS-P  
3. Weight and Body Mass Index 
3.01 BMI ≤ 30 kg/m2 using the calculation: BMI = weight (kg)/[height (m)]2 
4. Sex 
4.01 Male or female  
5. Contraceptives 
11DEC2020 CSR 1789-202-008
22

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
5.01 Female participants willing to minimize the risk of inducing pregnancy for the 
duration of the clinical study and follow-up period  
 A female participant is eligible to participate if she is not pregnant (has a negative 
urine pregnancy result prior to randomization), not breastfee ding, and at least one of 
the following conditions applies: 
a. Not a WOCBP as defined in Appendix 6 
OR 
b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 6 
during the treatment and follow-up period 
6.   
  
 
 
 
  
 
 
  
  
5.2. Exclusion Criteria 
Participants are excluded from the study if  any of the following criteria apply: 
1. Medical Conditions 
1.01 Any medical condition that may put the par ticipant at increased medical risk with 
exposure to BOTOX, including diagnosed myas thenia gravis, Eaton-Lambert syndrome, 
amyotrophic lateral sclerosis, or any othe r condition that might interfere with 
neuromuscular function  
1.02 Any uncontrolled medical condition  
1.03 An anticipated need for surgery or overnight hospitaliza tion during the study 
11DEC2020 CSR 1789-202-008
23

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
2. Prior/Concomitant Therapy 
2.01 An anticipated need for treatment with botuli num toxin of any serotype for any indication 
during the study (other th an study intervention)  
2.02 History of dental or surgical procedure for lower facial shaping or masseter muscle 
reduction 
2.03 Prior mid-facial and/or lower facial treat ment with nonpermanent soft tissue fillers, 
synthetic implantations, autologous fat transplantation, fat-reducing injectables, and/or skin-tightening laser treatments within 6 months prior to Day 1 
2.04 Current or planned dental or facial procedur es during the study period (eg, braces, dental 
implants, and reconstructive or aesthetic surg ery) that could interfere with MMPS, as 
determined by the investigator 
2.05 Facial hair or scarring (eg, acne) significan t enough to interfere with the 3D clinical 
imaging assessment, as determined by Canfield Scientific, Inc. 
3. Prior/Concurrent Clinical Study Experience 
3.01 Current enrollment in an investigational drug or device study or part icipation in such a 
study within 30 days of Day 1 
3.02 Prior exposure to botulinum toxin of any seroty pe to the masseter muscle or lower face at 
any time, or to any other part of the body within the 6 months prior to Day 1 
4. Diagnostic Assessments 
4.01 Current intraoral infection, including infec tion of the mouth or gum s, or facial skin 
infection requiring medical treatment in the opinion of the investigator  
4.02 History of or current TMJD, or presence of signs/symptoms of possible TMJD (see Section 8.2.5), in the opinion of  the investigator 
 
4.03 Weakness of the masseter, pterygoid, or tempor alis muscles due to trauma, facial nerve 
injury, or other condition that could interfere with normal chewing and jaw clenching, as 
determined by the investigator  
4.04 Excess lower facial fat, loose or lax skin in lower face, or  parotid gland prominence that 
could interfere with MMPS, as determined by the investigator  
4.05 Significant asymmetry of left and right side s of the face that could prevent identical 
MMPS grading on both sides of the face,  as determined by the investigator  
11DEC2020 CSR 1789-202-008
24

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
4.06  
 
4.07 Masseter prominence due to other etiologies (e g, parotid gland infection, parotiditis, 
malignancy) based upon findings from the oral exam ination (see Section 8.2.4) 
5.  
  
 
   
  
 
   
  
 
 
 
 
5.3. Lifestyle Considerations 
Not applicable; no restrictions are required. 
5.4. Screen Failures 
Screen failures are defined as participants who c onsent to participate in the clinical study but are 
not subsequently entered in the study. A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the CONSORT publishing 
requirements and to respond to queries from regulatory authorities. Minimal information 
includes demography, screen failure details, eligibility criteria, and any SAE. 
Individuals who do not meet the cr iteria for participation in this  study (screen failures) may not 
be rescreened.  
11DEC2020 CSR 1789-202-008
25

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
6. Study Intervention 
Study intervention is defined as any investig ational intervention(s) , marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to the 
study protocol. All investigators and site staff involved with pr eparation and injection of study 
interventions will receive training that is appropr iate to their role, and the training will be 
documented. 
6.1. Study Interventions Administered 
The study interventions administered are summar ized in Table 6–1 . 
Table 6–1 Study Interv entions Administered 
Study Intervention Name  BOTOX 48 U BOTO X 72 U Placebo 
Dosage Formulation BOTOX (botulinum 
toxin type A)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 BOTOX (botulinum toxin type A)  
 
 
 
 
 
 
 
 
 
 
 
 
 Placebo  
 
 
 
 
  
 
 
 
11DEC2020 CSR 1789-202-008
26

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Study Intervention Name  BOTOX 48 U BOTO X 72 U Placebo 
Unit Dose 
Strength(s)/Dosage 
Level(s) A total dose of 48 U 
(24 U/masseter) will be 
administered. 
 
 
 
 
 
 
 
 
 A total dose of 72 U 
(36 U/masseter) will be 
administered. 
 
 
 
 
 
 
 
  The total injection 
 
 
 
 
 
 
Route of Administration  Intramuscular Intramus cular  Intramuscular 
  
 
 
 
 
   
 
 
 
 
  
 
 
 
 
  
 
 
  
 
 
.   
 
 
  
 
   
 
 
  
 
 
Manufacturer Allergan Allergan Allergan 
 
 
 
To identify the masseter muscle treatment area, the investigator will first draw a line with a 
surgical marker from the corner of the mouth to a point at the inferior border of the ear, where 
the ear lobe attach es to the face (Figure 6-1, Lin e A). The investigator will instruct the 
participant to maximally clench his/her jaw (mout h closed and teeth together), and with visual 
inspection and manual palpation, will outline th e area of maximal bulge of the masseter muscle. 
11DEC2020 CSR 1789-202-008
27

 
 
Approval Date :  
 12-Feb-2019 
CONFI D
BOTOX 
The inve
which s h
parotid g
be mark e
point. T h
treatmen t
contralat
With the 
into the f
injectionand the 
v
each inj e
After co m
should a p
evidenc e
applied u
contralat
the injec t
 
Figure 6- 1
 
Immedi a
designee
DENTIAL 
stigator wil l
hould be loc a
gland (Figur e
ed as the fir s
he injection s
t area. In th e
eral masset e
participant n
first marked 
, the needle 
volume sho u
ection site, a n
mpleting th e
pply direct p
 of cutaneo u
until the ble e
eral masset e
tions for A E
1 Sche m
ately before d
) will write t
l mark the 3 
ated at or be l
e 6-1, Inject i
t injection s i
sites should b
e same man n
er muscle. 
no longer cl e
injection si t
direction w i
ld be distrib
n equal vol u
 3 injection s
pressure to t h
us bleeding o
eding stops. T
er muscle. T h
Es. 
matic of In jecti
dispensing t h
the particip a
injection sit
low Line A a
ion area [cir c
ite; 2 additi o
be spaced a p
ner, the inve s
enching his /
te perpendic u
ithin the mu s
uted within 
ume will be a
s of the mas s
he treatment 
or emerging 
The same p r
he participa n
ion Area 
 
he study int e
ant’s identifi c
es within th e
and posteri o
cled]). The b
onal injectio n
pproximatel y
stigator will 
/her jaw, the 
ularly to the 
scle bulk sh o
the deeper a
administere d
seter muscle
area for ap p
hematoma, 
rocedure wi l
nt should be 
ervention, t h
cation num b
e treatment a
or to the riso r
bulkiest poi n
n site marks
y 1 cm apar t
identify th e
 investigato r
full depth o
ould be per p
and more su p
d (see Table 
 on 1 side o f
proximately 
continued d i
ll be follow e
observed f o
he investigat o
ber and the dProto c
area on the m
rius and ant e
nt of the ma s
 will be ma d
t from each o
e 3 injection 
r will inject t
of the muscl e
pendicular a n
perficial mu s
6–2). 
f the face, t h
30 seconds. 
irect pressu r
ed for injecti
or at least 30
or (or appro p
date on the l acol 1789-20 2
masseter mu
erior to the 
sseter muscl e
de relative t o
other within
sites to the 
the needle t i
e. For each 
nd not obliq u
scle layers. F
he investigat o
If there is 
re should be 
on to the 
 minutes aft
priately trai n
abel. 2-008 
 
scle, 
e will 
o this 
n the 
ip 
ue, 
For 
or 
er 
ned 
11DEC2020 CSR 1789-202-008
28

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
6.1.1.  Other Study Supplies 
The following will be provided by the sponsor or designee: 
 Study intervention 
 Syringe labels 
 Temperature recording device for monitoring refrigerator temperature (if applicable) 
 Imaging equipment (supplied by a third-party vendor) 
 eCOA devices (supplied by a third-party vendor) 
The following will be provided by the study site: 
 Monitor and DVD player for viewing participant instructions. 
 Cotton pads and makeup remover 
 Alcohol wipes 
 Medical gloves 
 Urine pregnancy tests with a minimum sensitivity of 25 IU/mL 
 Sterile surgical marker pens 
 Appropriately-sized sterile needles and syringes for study intervention reconstitution 
and injection 
  
 Lockable refrigerator, to store study in tervention kits acco rding to the study 
manual  
 Covered container for discarded me dical waste materials (sharps box) 
 Internet connection (high-speed connection for eCRF completion) 
6.2. Preparation/Handling/Storage/Accountability 
 
 
  
 
Table 6–2 Injection Volume 
Study Intervention Total Dose (U); 
Total Volume 
(mL) Masseter Dose (U); 
Volume per 
Masseter (mL) Volume per 
Injection (mL) 
BOTOX 48 U    
 BOTOX 72 U   
Placebo (0 U)   
Detailed instructions on reconstitution and syringe preparation are provid ed in the Study Manual. 
11DEC2020 CSR 1789-202-008
29

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
The investigator or designee must confirm a ppropriate temperature conditions have been 
maintained during transit for all study interventi on received and any discrepancies are reported 
and resolved before use of the study intervention. 
Only participants enrolled in the study may receive study interven tion, and only authorized site 
staff may supply or administer study intervention.  All study intervention mu st be stored in a 
secure, environmentally controlled, and monito red (manual or automated) area in accordance 
with the labeled storage conditions with access lim ited to the investigator and authorized site 
staff. 
The investigator, institution, or  the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and reco rd maintenance (ie, 
receipt, reconciliation, and final disposition records).  
All unused study intervention must be stored secured, with limited access to a designated 
unblinded site member, and returned to the sponsor or designee once expired or at the 
termination of study. Unit counts will be perfor med when the study intervention is returned, and 
all study intervention must be accounted for. 
6.3. Measures to Minimize Bias: Randomization and Blinding 
At the Screening Visit, after the participant signs  the ICF, the site will log on to the IWRS to 
obtain a participant number. On Day 1, the IWRS will be used to manage the randomization and 
assignment of participants into  one of the 3 study intervention groups based on a randomization 
schedule prepared by the sponsor’s Biostatistics department. The randomization will occur after 
all baseline procedures have been  completed and the investigator has verified that the participant 
has met all inclusion and exclusion criteria. Randomization will be stratified at each investigator 
site by the participant’s baseline (Day 1) MMPS Gr ade (4 or 5), as assessed by the investigator. 
All study interventions will be provi ded in identical vials and cartons  to maintain blinding of the 
study. In addition, the injection volume and study intervention administration will be identical 
for all groups. 
At each study site, a designated staff member will  serve as the IDR who will be responsible for 
reconstituting the study interven tions and preparing and labeling the injection syringes. This 
person will be a staff member with no study re sponsibilities that require interaction with 
participants or with particip ant efficacy or safety data. 
The IDR will prepare the vial of study intervention as described in Sectio n 6.1 and the Study 
Manual. Based on the reconstitution requirements,  only the IDR will know the volume of diluent 
used for reconstitution. The IDR will not know whether the study intervention is BOTOX or 
placebo. Once the study intervention vial is reco nstituted, the IDR will draw the required volume 
into an appropriately sized syringe and label th e syringe with the participant’s ID number to 
11DEC2020 CSR 1789-202-008
30

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
ensure the investigator remains blinded based on reconstitution volume in the vial. The IDR will 
then provide the filled syringes to the investig ator, who will inject the participant according to 
the study intervention administra tion instructions in Section 6.1. 
Detailed instructions on reconstitution and syringe preparation will be provided in the Study 
Manual. 
The IWRS will be programmed with blind-breaking instructions. In case of an emergency, the 
investigator has the sole res ponsibility for determining if unbl inding of a participant’s study 
intervention assignment is warranted. Participant safe ty must always be the first consideration in 
making such a determination. If the investig ator decides that unblinding is warranted, the 
investigator should make every effort to contac t the sponsor prior to unblinding a participant’s 
study intervention assignment unless this could dela y emergency treatment of the participant. If a 
participant’s study intervention assignment is un blinded, the sponsor must be notified within 
24 hours after breaking the blind. The date a nd reason that the blind was broken must be 
recorded in the source documentation. 
6.4. Study Intervention Compliance 
The study investigator will administer all study in tervention injections to the participants.  
The study site will keep an accurate  study intervention disposition record. 
6.5. Concomitant Therapy 
Any medication or vaccine (including over-the-c ounter or prescription medicines, cannabis [in 
US states where its use is legal], vitamins, and/ or herbal supplements) that the participant is 
receiving at the time of enrollment or receives  during the study must be  recorded along with: 
 Indication/reason for medication use 
 Dates of administration incl uding start and end dates 
 Dosage information including dose and frequency 
  
 
  
 
 
11DEC2020 CSR 1789-202-008
31

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
 
11DEC2020 CSR 1789-202-008
32

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
6.6. Dose Modification 
Dose modification is not applicable. 
6.7. Intervention After the End of the Study 
No interventions after the e nd of the study are planned. 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal 
Participants may voluntarily withdraw from th e study at any time. A pr emature discontinuation 
will occur if a participant who signs the ICF a nd is dosed ceases participation in the study, 
regardless of circumstances, before the completion of the protocol-defin ed study procedures. 
Notification of early participant discon tinuation from the study and the reason for 
discontinuation will be made to the sponsor and will be clearly documented on the appropriate 
eCRF. 
Reasons for discontinuation from the study in tervention and/or the study may include the 
following commonly used or other acceptable terms: 
11DEC2020 CSR 1789-202-008
33

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Commonly Used Terms Other Acceptable Terms 
Adverse event Death 
Lack of efficacy  
Lost to follow-up  
Other  
Physician decision  
Pregnancy  
Protocol deviation  
Site terminated by sponsor  
Study terminated by sponsor  
Withdrawal by participant  
If a pregnancy is confirmed afte r the participant has received study intervention, the participant 
may choose to exit the study after appropriate safety follow-up or to remain in the study for all 
safety and efficacy follow-up assessments through the end-of-study visit.   
Definitions of the standard terms are provided in Appendix 4. 
7.1. Discontinuation of Study Intervention 
Not applicable, as participants receive only a single treatment with study intervention on Day 1. 
7.2. Participant Discontinuation/Withdrawal from the Study 
 A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, 
or administrative reasons. 
 If the participant withdraws consent for disclo sure of future information, the sponsor may 
retain and continue to use a ny data collected before such  a withdrawal of consent. 
 If a participant exits the study early, every effort  should be made to ensure a Study Exit Visit 
and associated measures are pe rformed - see the SoA ( for data to be collected at 
the time of study discontinuation. 
 Notification of early participant discon tinuation from the study and the reason for 
discontinuation will be made to the spons or and will be clearly documented on the 
appropriate eCRF. 
7.3. Lost to Follow Up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. 
11DEC2020 CSR 1789-202-008
34

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit: 
11DEC2020 CSR 1789-202-008
35

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
8. Study Assessments and Procedures 
 Study procedures and their timing ar e summarized in the SoA (  Protocol waivers 
or exemptions are not allowed. 
 Evaluations are to be performed by the same evaluator throughout the study whenever 
possible. If it is not possible to use the same evaluator to follow the participant, then 
evaluations should overlap (exami ne the participant t ogether and discuss findings) for at least 
1 visit. 
 Immediate safety concerns should be discussed with the sponsor immediately upon occurrence or awareness to determine if the part icipant should continue or discontinue study 
intervention. 
 Adherence to the study design requirements, includi ng those specified in the SoA, is essential 
and required for study conduct. 
 All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened a nd to confirm eligibility or record reasons for 
screening failure, as applicable. 
8.1. Efficacy Assessments 
Planned timepoints for all efficacy assessmen ts are provided in the SoA (  The 
measures are described in detail in Appendix 7  and Appendix 8. 
Evaluations of MMPS-P,  completed at screening and baseline will be 
used for test-retest evaluations of the tools.  
8.1.1.  Primary Efficacy Assessment 
The primary efficacy assessment is to be completed at screening, baseline, and at each scheduled 
visit thereafter until study exit. 
Note: The Day 1 images will be used as the baseline images. If the baseline images are not of 
acceptable quality, the screening images will be used instead. Canfield Scientific, Inc. must 
approve each participant’s screening images to ensu re a quality baseline image is available in the 
event that the Day 1 images are not of accepta ble quality. If the screening images are not 
acceptable, 1 retake is permitted and must be taken before Day 1.  
11DEC2020 CSR 1789-202-008
36

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
MMPS 
The primary efficacy assessment is masseter muscle prominence assessed by the investigator 
using the MMPS (1 = minimal, 2 = mild, 3 = moderate, 4 = marked, 5 = very marked; see 
Appendix 7 for details). The MMPS assessment will be completed via electronic tablet provided 
to the study site. 
The MMPS is evaluated for each masseter (ie, right and left) separately every time it is rated. 
8.1.2.  Secondary Efficacy Assessments 
MMPS-P and lower facial volume assessments will be completed at screening, baseline, and at 
each scheduled visit thereafter until study exit. The PSAC will be completed at all scheduled 
postbaseline visits (Days 30, 60, 90, 120, 150, a nd 180). Participants will view a training video 
on how to properly complete the MMPS-P and PSAC assessments using photos, at the Screening 
Visit (and at other visits if needed).  
For MMPS-P and PSAC, the participant will answer questions via electronic tablet that will be 
provided to the study partic ipant at the study site. 
MMPS-P 
MMP assessed by the participant is a secondary efficacy assessment developed by the sponsor 
through concept elicitation and cognitive debr iefing in accordance with the FDA Patient 
Reported Outcomes guidance. Participants will be asked to assess the severity of their masseter 
prominence using a single question composed of 5 severity grades (1 = not at all pronounced, 
2 = mildly pronounced, 3 = moderately pronounced , 4 = pronounced, 5 = very pronounced; see 
Appendix 8 for details) and a 2D image of their face collected at th e current visit.  
The MMPS-P is evaluated for both masseters as a single score. 
Evaluations of MMPS-P completed at screening and baseline will be used for test-retest 
reliability assessment of the tool. PSAC 
The PSAC is a commonly used assessment of cha nge scale that has been adapted for use with 
MMP by the sponsor using concept elicitation and cognitive debriefing. Participants will be 
asked to assess change of their lower face shape using images taken before study intervention (ie, 
baseline, or screening if the baseline image is not of acceptable quality) and after study 
intervention (ie, the current study visit) taking into  consideration the bottom half of the face from 
the top of the cheeks to the chin. The PSAC gr ades are as follows: 3 = much improved, 
2 = moderately improved, 1 = minimally improved, 0 = change, -1 = minimally worse, -2 = moderately worse, and -3 = much worse (see Appendix 8 for details).  
11DEC2020 CSR 1789-202-008
37

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Lower Facial Volume 
Lower facial volume will be calculated by a qualified technician (from Canfield Scientific, Inc.) 
using 3D image models using 2 analysis methods. 
Investigators will follow training/instructions for use of the digital imaging system as provided 
by Canfield Scientific, Inc. 
8.1.3.  Other/Exploratory Efficacy Assessments 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
11DEC2020 CSR 1789-202-008
38

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
11DEC2020 CSR 1789-202-008
39

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 
 
  
Exit Interviews 
Participant exit interviews will be completed at the Study Exit visit by contract research 
organization personnel. Open-ended interviews will be conducted to collect data about impacts 
of the study intervention and meaningful change on their MMP. All interv iews will be recorded 
for thematic analysis. Results will be summarized in a separate report. 
8.2. Safety Assessments 
Planned timepoints for all safety assessmen ts are provided in the SoA (  
8.2.1.  Vital Signs 
Vital signs will be assessed as follows: 
 Pulse rate, respiratory rate, and blood pressure will be assessed. 
 Blood pressure and pulse measurements will be  assessed with participants in a sitting 
position after sitting for at least 5 minutes; use of either  a manual or automated device is 
acceptable. Manual techniques will be used onl y by adequately trained personnel; whenever 
possible, the same person should perform all manual assessments as much as possible. 
8.2.2.  Height and Weight 
Height and weight will be measured and recorded, and BMI calculated. 
8.2.3.  Pregnancy Testing 
Urine pregnancy testing will be conducted at th e screening, baseline, and study exit visits. 
Females of childbearing potential must have a negative test result before receiving the study 
intervention. This test may also be performed at any other visit, at the in vestigator’s discretion. 
At each visit, the investigator should discuss contraceptive use compliance with females of 
childbearing potential. 
8.2.4.  Oral Examination 
As referenced in Exclusion criterion 4.07, oral examinations will be conducted at the Screening 
Visit, in order to rule out other potential etiologies for MMP, such as malignancy. The 
investigator will assess extraorally for parotid gl and tumors, parotiditis (gland or duct), lipoma, 
sialolith (stones), or osseous remodeling at the gonial angle includi ng bone protrusion, and 
intraorally for osseous lesions in the angle of th e mandible behind the molars , or for expansion of 
11DEC2020 CSR 1789-202-008
40

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
alveolar bone supporting the teeth. The examinati on procedures are described in greater detail in 
the Study Manual.  
8.2.5.  Screening for TMJD 
Screening for signs/symptoms of possible TMJD will be conducted by the investigator at the 
Screening Visit, as described in the Study Ma nual. Depending on the findings, the investigator 
may decide to exclude the participant from the study (per exclusion crite rion 4.02), or may refer 
the participant to a dentist for further TMJD screening, to be completed prior to Day 1. The participant may complete the rest of the planned activities and procedures for the Screening Visit, 
with the dentist examination occurring at a la ter time in the screeni ng period. If, based on 
findings from a dental examination, the dent ist diagnoses the participant with TMJD, the 
participant will be considered a screen failure. 
8.3. Adverse Events and S erious Adverse Events 
The definitions of an AE or SAE can be found in Appendix 2. 
AEs will be reported by the participant (or, when  appropriate, by a caregiver, surrogate, or the 
participant’s legally authorized representative). 
The investigator and any qualified designees ar e responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and any other study-specific terms as 
relevant and remain responsible for following up AE s that are serious, considered related to the 
study intervention or study procedures, or that caused the participant to discontinue the study 
intervention or study (see Section 7). 
8.3.1.  Time Period and Frequency for Collecting Adverse Event and Serious Adverse 
Event Information 
All AE/SAEs from the signing of th e ICF will be collected at the timepoints specified in the SoA 
 and as observed or reported spontaneously by st udy participants. 
Medical occurrences that begin before the start of study intervention, but after obtaining 
informed consent will be recorded in the AE  section of the eCRF and will be considered 
pretreatment AEs. 
All SAEs will be recorded and reported to the sp onsor or designee within 24 hours, as indicated 
in Appendix 2 . The investigator will subm it any update d SAE data to the sponsor within 
24 hours of it being available. Investigators are not obligated to  actively seek AE or SAE information after conclusion of the 
study participation. However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she cons iders the event to be 
11DEC2020 CSR 1789-202-008
41

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
reasonably related to the study intervention or study participation, the investigator must promptly 
notify the sponsor. 
The method of recording, evaluating, and a ssessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 2. 
8.3.2.  Method of Detecting Adverse Events and Serious Adverse Events 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of  the participant is the preferred method to inquire about 
AE occurrences. 
8.3.3.  Follow-up of Adverse Events and Serious Adverse Events 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. A ll SAEs and AESIs as defined in Appendix 2 will be followed 
until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-
up (as defined in Section 7.3). 
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the sponsor to 
elucidate the nature and/or causa lity of the AE or SAE as fully as possible. This may include 
additional laboratory tests or inve stigations, histopathological exam inations, or consultation with 
other health care professionals. 
If a participant dies during participation in th e study or during a recognized follow-up period, the 
investigator will provide the sponsor with  a copy of any postmortem findings including 
histopathology. 
New or updated information will be record ed in the originally completed eCRF. 
The investigator will submit any updated SAE data to the sponsor within 24 hours of receipt of 
the information. 
8.3.4.  Regulatory Reporting Requirements for Serious Adverse Events 
 Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibil ities towards the safety of participants and the safety of a 
study intervention under clinical  investigation are met.  
 The sponsor has a legal responsibility to notify both the local regulator y authority and other 
regulatory agencies about the safety of a study intervention under clinical  investigation. The 
sponsor will comply with country-specific re gulatory requirements relating to safety 
reporting to the regulatory authority , IRBs/ IECs, and investigators. 
11DEC2020 CSR 1789-202-008
42

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regu latory requirements and sponsor policy and 
forwarded to investigators as necessary. 
 An investigator who receives an investigator  safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from th e sponsor will review 
and then file it along with the investigator’s  brochure and will notify the IRB/IEC, if 
appropriate according to local requirements. 
8.3.5.  Pregnancy 
 If a pregnancy is confirmed after the partic ipant has received the study intervention, the 
participant may choose to exit th e study after appropriate safety follow-up or to remain in the 
study for all safety and efficacy follow-up a ssessments through the end-of-study visit. 
 Details of all pregnancies in female participan ts will be collected from the signing of the ICF 
and through the duration of the pregnancy . 
 If a pregnancy is reported, the investigator  should inform the sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlin ed in Appendix 6 . 
 Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs. 
8.3.6.  Protocol-Specific Adverse Events  
The investigator should refer a participant to a qualified dentist for further evaluation in the case 
of severe (as defined in Appendix 2) mastication disorders (eg, severe reports of chewing 
weakness, abnormal chewing, difficulty chewing). For any referral, the investigator must obtain 
findings from the dentist for complete AE documentation in the eCRF. 
8.3.7.  Adverse Events of Special Interest 
AESI will be reported as indicated in  Appendix 2. 
8.3.8.  Medication Errors 
Medication error refers to any unintended error in the dosing and/or administration of the study 
intervention as per instructions in the protocol, for example: 
 Wrong study intervention 
 Wrong dose (including dosing regi men, concentration, amount) 
 Wrong participant (ie, not administer ed to the intended participant) 
11DEC2020 CSR 1789-202-008
43

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
8.4. Treatment of Overdose 
The LD 50 for BOTOX in humans is estimated from primate studies to be approximately 3000 U. 
This makes accidental injection of a lethal dose  highly unlikely, but significant AEs may still 
occur at doses below the LD 50 (Herrero 1967, Scott 1989). 
Excessive doses may produce local or distan t, generalized, and profound neuromuscular 
paralysis. Should accidental injection or oral ingestion occur or over dose be suspected, the 
participant should be medically monitored for up to several weeks for progressive signs or 
symptoms of systemic muscular weakness that could be local or distant from the site of injection, 
and which may include ptosis, diplopia, dyspha gia, dysarthria, generalized weakness, or 
respiratory failure. Please refer to the genera l Section 6.5 of the BO TOX MMP investigator’s 
brochure for further details. 
In the event of an overdose,  the investigator should: 
1. Contact the medical safety  physician immediately. 
2. Closely monitor the participant for AEs and SAEs. 
3. Document the quantity of the excess dose as well as the duration of  the overdose in the 
eCRF as well as other details that led to the overdose. 
8.5. Pharmacokinetics 
PK parameters are not evaluated in this study. 
8.6. Pharmacodynamics 
Pharmacodynamic parameters are not evaluated in this study. 
8.7. Genetics 
Genetics are not evaluated in this study. 
8.8. Biomarkers and Other Assessments 
Biomarkers are not evaluated in this study. 
8.9. Health Economics  
Health economics parameters are not evaluated in this study. 
11DEC2020 CSR 1789-202-008
44

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
9. Statistical Considerations 
9.1. Statistical Hypotheses 
The following set of hypotheses will be used to compare the BOTOX groups with placebo: 
 Null hypothesis: BOTOX and placebo are e qually effective in reducing MMP as 
measured by the proportion of responders achieving MMPS Grade ≤ 3 at Day 90. 
 Alternative hypothesis: BOTOX and placebo are not equally effective in reducing MMP 
as measured by the proportion of responders achieving MMPS Grade ≤ 3 at Day 90. 
9.2. Sample Size Determination 
The primary efficacy parameter is the propor tion of responders who achieve MMPS Grade ≤ 3 at 
Day 90. Based on previous data from Study 191622-130 and the assumption of a difference of 
≥ 34% in MMPS responder rate between BOTOX 48 U or 72 U and placebo group, 
approximately 50 participants per study intervention group will  provide > 90% power using a 
2-sided Mantel-Haenszel test, 10% dr opout rate, and 5% significance level. 
Approximately 225 participants will be screened to achieve 150 enrolled to study intervention 
and 135 evaluable participants for an estimated to tal of 45 evaluable participants per intervention 
group.  
9.3. Populations for Analyses 
The analysis populations will consist of  participants as defined below: 
 The mITT population includes all randomized participants with ≥ 1 postbaseline MMPS 
assessment. Participants will be summarized according to the randomized study 
intervention. 
 The safety population includes all treated participants who receive ≥ 1 administration of 
study intervention. Participants will be summ arized according to the study intervention 
they actually received. 
9.4. Statistical Analyses 
The SAP will be developed and finalized before database lock and unblinding and will describe 
the participant populations to be included in the analyses, and procedures for accounting for 
missing, unused, and spurious data. This section is  a summary of the planned statistical analyses 
of the primary and secondary endpoints.  
11DEC2020 CSR 1789-202-008
45

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
9.4.1.  Efficacy Analyses 
The efficacy analyses will be based on the mITT population.  The last-observation-carried-
forward approach will be used to impute missing postbaseline values. Baseline for efficacy is 
defined as the last nonmissing efficacy assessment before the first dose of  study intervention. All 
statistical tests will be 2-sided hypothesis test s performed at the 5% level of significance for 
main effects. 
9.4.1.1. Analysis Endpoints 
The primary and secondary efficacy endpoints are lis ted below, and analyses will be defined in 
the following sections. All analyses for other e fficacy endpoints listed below will be defined in 
the SAP. 
Primary efficacy endpoint: 
 Proportion of responders who achieve MMPS Grade ≤ 3 at Day 90 
Secondary efficacy endpoints:  Proportion of responders who achieve MMPS-P Grade ≤ 3 at Day 90 
 Proportion of responders who achieve ≥ 2-grade MMPS improvement from baseline at 
Day 90 
 Proportion of responders who achieve ≥ 2-grade MMPS-P improvement from baseline at 
Day 90 
 Proportion of responders who achieve PSAC Grade ≥  2 (at least moderately improved from 
baseline) at Day 90 
 Change from baseline in lower facial volum e at Day 90 (calculated from standardized 
images) 
Other efficacy endpoints: 
  
   
  
 
 
 
11DEC2020 CSR 1789-202-008
46

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 
 
 
 
 
9.4.1.2. Primary Analyses 
The prim
ary efficacy endpoint will be the proportion of responders who achieve MMPS 
Grade ≤ 3 at Day 90 and will be analyzed using Cochran-Mantel-Haenszel model stratified by 
baseline MMPS Grade (4 or 5). Each BOTOX do se will be compared with placebo separately. 
9.4.1.3. Secondary Analyses 
The following secondary variables will be analy zed at Day 90 using the same method as the 
primary analysis: 
 Proportion of responders who achieve MMPS-P Grade ≤ 3 
 Proportion of responders who achieve ≥ 2-grade MMPS improvement from baseline 
 Proportion of responders who achieve ≥ 2-grade MMPS-P improvement from baseline  
 Proportion of responders who achieve PSAC Grade ≥  2 
The change from baseline in lower facial volume at Day 90 (calculated from standardized images 
and analyzed by 2 methods) will be statisti cally analyzed using ANCOVA with study 
intervention group and investigator  sites as factors and baseline MMPS Grade (4 or 5) as a 
covariate. 
9.4.2.  Safety Analyses 
The safety analysis will be performed using the sa fety population and will be fully defined in the 
SAP. The safety parameters include AEs and vital signs (pulse rate, re spiratory rate, and blood 
pressure). For vital signs, the last nonmissing assessment before the study intervention will be 
used as the baseline for all analyses. 
9.4.2.1. Adverse Events 
An AE will be considered a TEAE if: 
 The AE began on or after the date of the first dose of st udy intervention; or 
11DEC2020 CSR 1789-202-008
47

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 The AE was present before the date of the firs t dose of study intervention, but increased in 
severity or became serious on or after the date of the first dose of study intervention. 
An AE will be considered a TESAE if it is a TEAE that additionally meets any SAE criteria. 
The number and percentage of participants re porting TEAEs in each study intervention group 
will be tabulated by system organ class and prefe rred term and by system organ class, preferred 
term, and severity. 
The number and percentage of participants re porting treatment-related TEAEs in each study 
intervention group will be tabulated by sy stem organ class and preferred term. 
If more than 1 AE is coded to the same preferred term for the same participant, the participant 
will be counted only once for that preferred term using the most severe and most related 
occurrence for the summarizations by severity and by relationship to study intervention. 
Summary tables will be provided fo r participants with SAEs and pa rticipants with AEs leading to 
discontinuation if 5 or more participants reported  such events. Listings of all AEs, SAEs, and 
AEs leading to discontinuation by pa rticipant will be presented. 
The definitions of an AE and SAE can be found in Appendix 2. 
9.4.2.2. Vital Signs 
Descriptive statistics for vital si gns (systolic and diastolic BP, pulse  rate, and respiratory rate) at 
baseline and changes from baseline at each assessment will be presented by study intervention. 
Vital sign values will be considered to be PCS if they meet both the obs erved-value criteria and 
the change-from-baseline-value criteria that will be detailed in the SAP. The number and 
percentage of participants who have PCS postbas eline vital sign values will be tabulated by study 
intervention for each assessment. The percentages will be calculated relative to the number of 
participants who have availabl e non-PCS baseline values and at least 1 postbase line assessment. 
The numerator will be the total number of particip ants with at least 1 PCS postbaseline value. A 
supportive listing of participants with PCS postbas eline values will be provided for the safety 
population. 
9.4.3.  Other Analyses 
All other analyses will be described in the SAP.  
9.5. Interim Analyses 
Interim analyses are not planned for this study. 
11DEC2020 CSR 1789-202-008
48

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10. Supporting Documentation and Operational Considerations 
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations 
10.1.1. Regulatory and Ethical Considerations 
 This study will be conducted in accordance w ith the protocol and with the following: 
o Consensus ethical principles derived fr om international gui delines including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines 
o Applicable ICH/ISO GCP guidelines 
o Applicable laws and regulations 
 The protocol, protocol amendments, ICF, i nvestigator’s brochure, and other relevant 
documents (eg, advertisements) must be submitted to an IRB/IEC by the investigator and 
reviewed and approved by the IRB/IEC before the study is initiated. 
 Any amendments to the protocol will requir e IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to e liminate an immediate 
hazard to study participants.  
 The investigator will be re sponsible for the following: 
o Providing written summaries of the status of  the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC 
o Notifying the IRB/IEC of SAEs or other sign ificant safety findings as required by 
IRB/IEC procedures 
o Providing oversight of the overall conduct of the study at the site and adherence to 
requirements of applicable local regulations, for example 21 CFR, ICH guidelines, the 
IRB/IEC, and European regulation 536/2014 for clinical studies (if applicable) 
10.1.2. Financial Disclosure 
Investigators and subinvestigators will provide th e sponsor with sufficient, accurate financial 
information as requested to allow the sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appr opriate regulatory author ities. Investigators are 
responsible for providing information on financial interests during the cour se of the study and for 
1 year after completion of the study. 
11DEC2020 CSR 1789-202-008
49

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.1.3. Informed Consent Process 
 The investigator or his/her representative will explain the nature  of the study to the 
participant or his/her legally authorized repres entative and answer all questions regarding the 
study.  
 Participants must be informed that their part icipation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HIPAA requi rements, where applicable, and the IRB/IEC 
or study center.  
 The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. 
The authorized person obtain ing the informed consent must also sign the ICF. 
 Participants must be re-consented to the most  current version of th e ICF(s) during their 
participation in the study.  
 A copy of the ICF(s) must be pr ovided to the participant.  
10.1.4. Data Protection 
 Participants will be assigned a unique identifier . Any participant records or datasets that are 
transferred to the sponsor will contain the identifier only; participant names or any 
information which would make the participan t identifiable will not be transferred.  
 The participant must be informed that his/her personal study-related data will be used by the 
sponsor in accordance with local data protecti on law. The level of disclosure must also be 
explained to the participant.  
 The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other author ized personnel appointed by the sponsor, by 
appropriate IRB/IEC members, and by in spectors from regulatory authorities. 
10.1.5. Posting Clinical Study Data 
 Study data and information may be published in  nonpromotional, peer-reviewed publications 
either by or on behalf of the sponsor.  
 Clinical study reports, safety updates, and a nnual reports will be pr ovided to regulatory 
authorities as required. 
 Company-sponsored study information and tabul ar study results will be posted on the US 
National Institutes of Health's  website www.ClinicalTrials.gov  and other publicly accessible 
sites 
10.1.6. Data Quality Assurance 
 All participant data relating to the study will be recorded on printed or electronic CRFs unless transmitted to the sponsor or designee elec tronically. The investigator is responsible 
11DEC2020 CSR 1789-202-008
50

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
for verifying that data entries are accurate a nd correct by physically or electronically signing 
the CRF.  
 The investigator must maintain accurate do cumentation (source data) that supports the 
information entered in the CRF.  
 The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
 The sponsor or designee is res ponsible for the data management of this study including 
quality checking of the data.  
 Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorized site personnel are ac curate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the curren tly approved protocol and any other study 
agreements, ICH GCP, and all app licable regulatory requirements.  
 Records and documents, including signed ICFs, pe rtaining to the conduct of this study must 
be retained by the investigator as stated in th e clinical trial agreement. No records may be 
destroyed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or part y without written notification to the sponsor.  
10.1.7. Source Documents 
 Source documents provide evidence for the existe nce of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site. 
 Data reported on the CRF or entered in the e CRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medi cal records or transfer  records, depending on 
the study.  
 Definition of what constitutes source data can  be found in Section 4.0 of ICH E6, Good 
Clinical Practice: Consolidated Guidance and must follow ALCOA, ie, records must be attributable, legible, contempor aneous, original, and accurate. 
10.1.8. Study and Site Closure 
The sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of th e sponsor. Study sites will be closed upon study 
completion. A study site is considered closed  when all required documents and study supplies 
have been collected and a study-site  closure visit has been performed. 
The investigator may initiate st udy-site closure at any time, pr ovided there is reasonable cause 
and sufficient notice is given in ad vance of the intended termination. 
11DEC2020 CSR 1789-202-008
51

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Reasons for the early closure of a study site by the sponsor or investigat or may include but are 
not limited to: 
 Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the sponsor ’s procedures, or GCP guidelines 
 Inadequate recruitment of participants by the investigator 
 Discontinuation of further study intervention development 
10.1.9. Publication Policy 
 Allergan as the sponsor has proprietary intere st in this study. Authorship and manuscript 
composition will reflect joint cooperation betw een multiple investig ators and sites and 
Allergan personnel. Authorship will be establis hed prior to the writing of the manuscript. As 
this study involves multiple centers, no individu al publications will be allowed prior to 
completion of the final report of the multicen ter study except as agreed with Allergan. 
 The sponsor will comply with the requirem ents for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. 
 Authorship will be determined by mutual agre ement and in line with International Committee 
of Medical Journal Editors authorship requirements. 
10.1.10. Compliance with Protocol 
The investigator is responsible for compliance wi th the protocol at the investigational site. A 
representative of the sponsor will make freque nt contact with the investigator and his/her 
research staff and will conduct regular monitoring visits at the site to review participant and 
study intervention accountability records for complia nce with the protocol. Protocol deviations 
will be discussed with the investigator upon identification. The use of the data collected for the 
participant will be discussed to determine if th e data are to be included in the analysis. The 
investigator will enter data that may be excl uded from analysis as defined by the protocol 
deviation specifications. Signifi cant protocol deviations will  be reported to the IRB/IEC 
according to the IRB/IEC’s reporting requirements. 
11DEC2020 CSR 1789-202-008
52

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.2. Appendix 2: Adverse Events: De finitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting 
Definition of AE 
AE Definition 
 An AE is any untoward medical occurrence in  a patient or clini cal study participant, 
temporally associated with the use of study in tervention, whether or not considered related 
to the study intervention. 
 An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with 
the use of study intervention. 
AESI  
An AESI is an AE of scientific and medi cal relevance specific to the sponsor’s study 
drug/device or program, which may warrant ongoing monitoring. Such an event might warrant 
further investigation in order to characterize and understand it.  
Facial muscle paralysis (NOT including a weak or altered smile) has been identified as an 
AESI for the study interventi on in this protocol.   
Suspected AESIs should be reported to the sponsor  as a typical adverse event. No AESI form 
is needed. 
If the AESI meets SAE criteria (which are listed below) , it should be reported within 24 hours. 
 
Events Meeting the AE Definition  
 Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition 
 New condition detected or diagnosed after st udy intervention admi nistration even though 
it may have been present before the start of the study 
 Signs, symptoms, or the clinical sequel ae of a suspected drug-drug interaction 
 Lack of efficacy or failure of expected pharm acological action per se will not be reported 
as an AE or SAE. Such instances will be captured in the efficacy assessments.  
 
11DEC2020 CSR 1789-202-008
53

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Events NOT Meeting the AE Definition  
 Medical or surgical procedure (eg, endoscopy,  appendectomy): the condition that leads to 
the procedure is the AE 
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital) 
 Anticipated day-to-day fluctuations of pre-existing disease(s) or c ondition(s) present or 
detected at the start of the study that do not worsen 
Definition of SAE 
SAEs must meet both the AE criteria described a bove and the seriousness criteria listed below. 
An SAE is defined as any untoward medical occurrence that, at any dose: 
a. Results in death 
b. Is life threatening 
The term life threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It  does not refer to an event, which hypothetically 
might have caused death, if it were more severe. 
c. Requires inpatient hospitalization or prolongation of existing hospitalization 
In general, hospitalization signifies that the participant has been detained (usually involving at 
least an overnight stay) at the hospital or em ergency ward for observation and/or intervention 
that would not have been appropriate in the physician’s office or  outpatient setting. 
Complications that occur during hospitaliza tion are AEs. If a complication prolongs 
hospitalization or fulfills any other serious criter ia, the event is serious. When in doubt as to 
whether hospitalization o ccurred or was necessary, the AE should be considered serious. 
Hospitalization for elective intervention of a pr e-existing condition that did not worsen from 
baseline is not considered an AE. 
d. Results in persistent disability/incapacity 
 The term disability means a substantial disr uption of a person’s abil ity to conduct normal 
life functions. 
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or  prevent everyday life 
functions but do not constitute a substantial disruption.
 
e. Is a congenital anomaly/birth defect 
11DEC2020 CSR 1789-202-008
54

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
f. Other situations: 
 Medical or scientific judgment should be ex ercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be 
immediately life threatening or result in death or hospitalization but may jeopardize the 
participant or may require medical or surgic al intervention to prev ent one of the other 
outcomes listed in the above definition. These events should usually be considered serious.
Examples of such events include invasive or  malignant cancers, intensive intervention in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in  hospitalization, or development of drug dependency or 
drug abuse.
 
Recording and Follow-Up of AEs and/or SAEs 
AE and SAE Recording 
 When an AE or SAE occurs, it is the respons ibility of the investig ator to review all  
documentation (eg, hospital progress notes, la boratory reports, and diagnostics reports) 
related to the event. 
 The investigator will then record all rele vant AE or SAE information in the eCRF. 
 It is not acceptable for the investigator to send photocopies of the pa rticipant’s medical 
records to Allergan in lieu of completion of the AE or SAE eCRF page. 
 There may be instances when copies of medi cal records for certain cases are requested by 
Allergan. In this case, all participant iden tifiers, with the exception of the participant 
number, will be redacted on the copies of  the medical records before submission to 
Allergan. 
 The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information.  Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
 
11DEC2020 CSR 1789-202-008
55

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Assessment of Intensity 
MILD A type of AE that is usually transi ent and may require only minimal treatment or 
therapeutic intervention. Th e event does not generally interfere with usual activities 
of daily living. 
MODERATE A type of AE that is usually a lleviated with additional specific therapeutic 
intervention. The event in terferes with usual activities of daily living, causing 
discomfort but poses no significant or perm anent risk of harm to the research 
participant. 
SEVERE A type of AE that interrupts usual activ ities of daily living, or significantly affects 
clinical status, or may require in tensive therapeutic intervention. 
An event is defined as serious  when it meets at least one of the predefined outcomes as 
described in the definition of an SA E, NOT when it is rated as severe. 
 
Assessment of Causality 
 The investigator is obligated to assess th e relationship between study intervention and each 
occurrence of each AE or SAE. 
 A reasonable possibility  of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, ra ther than a relationshi p cannot be ruled out. 
 The investigator will use clinical judgment to determine the relationship. 
 Alternative causes, such as underlying diseas e(s), concomitant therapy, and other risk 
factors, as well as the temporal relati onship of the event to study intervention 
administration will be considered and investigated. 
 The investigator will also consult the investig ator’s brochure and/or product information, 
for marketed products, in his/her assessment. 
 For each AE or SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE or SAE and has pr ovided an assessment of causality. 
 There may be situations in which an SAE ha s occurred and the investigator has minimal 
information to include in the initial report to Allergan. However, it is very important that 
the investigator always make an assessmen t of causality for every event before the 
initial transmission of the SAE data to Allergan. 
 The investigator may change his/her opinion of causality in light of follow-up information 
and send an SAE follow-up report with  the updated causality assessment. 
 
11DEC2020 CSR 1789-202-008
56

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 The causality assessment is one of the criteria  used when determining regulatory reporting 
requirements.  
Reporting of SAEs 
SAE Reporting 
 Email is the preferred met hod to transmit SAE information. The email address is 
 
 Facsimile transmission of the SAE information is also acceptable. The fax number is +1-
(backup number is ).  
 Contacts for SAE reporting can be found on the protocol title page.  
 
11DEC2020 CSR 1789-202-008
57

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.3. Appendix 3: Abbreviations 
Abbreviation/Term Definition 
2D 2-dimensional 
3D 3-dimensional 
AE adverse event 
AESI adverse event of special interest 
ALCOA attributable, legible, contemporaneous, original, accurate 
ANCOVA analysis of covariance 
AOI area of interest 
BMI body mass index 
BOTOX Botulinum toxin type A purified neurotoxin 
BP blood pressure 
CDISC Clinical Data Interchange Standards Consortium 
CFR Code of Federal Regulations 
CIOMS Council for International Organizations of Medical Sciences 
COA clinical outcome assessments  
CONSORT Consolidated Standards of Reporting Trials  
CT computed tomography 
DVD digital versatile disc 
eCOA electronic clinical outcome assessment (via tablet) 
eCRF electronic case report form 
FDA Food and Drug Administration 
FSH follicle-stimulating hormone 
GCP Good Clinical Practice 
HIPAA Health Insurance Portability and Accountability Act 
HRT hormonal replacement therapy 
ICF informed consent form 
ICH International Council on Harmonisation 
ID identification 
IDR independent drug reconstitutor 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
ISO International Organization for Standardization 
IWRS interactive web response system 
LD 50 lethal dose, 50% 
  
  
  
11DEC2020 CSR 1789-202-008
58

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
  
  
mITT modified intent-to-treat 
MMH masseter muscle hypertrophy 
MMP masseter muscle prominence 
MMPS Masseter Muscle Prominence Scale 
MMPS-P Masseter Muscle Prominence Scale - Participant 
MRI magnetic resonance imaging 
NCI National Cancer Institute 
PCS potentially clinically significant 
  
PK pharmacokinetic 
PRO patient-reported outcomes 
PSAC Participant Self-Assessment of Change 
SAE serious adverse event 
SAP statistical analysis plan 
SOA Schedule of Activities 
SUSAR suspected unexpected serious adverse reaction 
TEAE treatment-emergent adverse event 
TESAE treatment-emergent serious adverse event 
TMJD temporomandibular joint disorders  
U unit 
US United States 
WOCBP woman of childbearing potential 
  
 
11DEC2020 CSR 1789-202-008
59

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.4. Appendix 4: Standard Discontinuation Criteria 
This table provides participant discontinuation cr iteria for this protocol . CDISC terminology is 
used, and thus subject  or patient is used instead of participant  (as used elsewhere in this 
protocol). These terms are interchangeable. 
CDISC Submission Value CDISC Definition 
Adverse event Any untoward medical occurrence in a patient or clinical investigation 
participant administered a pharmaceu tical product and which does not 
necessarily have a causal relationship with this treatment. An AE can 
therefore be any unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally asso ciated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product. For further information, see the ICH Guideline for Clinical Safety Data Management: De finitions and Standards for Expedited 
Reporting (modified from ICH E2A)  Synonyms: side effect, adverse 
experience. See also serious adverse event, serious adverse experience. (CDISC glossary) 
Completed To possess every necessary or normal part or component or step; having 
come or been brought to a conclusion (NCI) 
Death The absence of life or state of being dead (NCI) 
Lack of efficacy The lack of  expected or desired effect  related to a therapy (NCI) 
Lost to follow-up The loss or lack of continuation of a participant to follow-up 
Other Different than the one(s) previously specified or mentioned (NCI) 
Physician decision A position, opinion or judgment reached after consideration by a physician with reference to participant (NCI) 
Pregnancy Pregnancy is the state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth. (NCI) 
Protocol deviation An event or decision that stands in contrast to the guidelines set out by the protocol (NCI) 
Site terminated by sponsor An indication that a clinical study was stopped at a particular site by its sponsor (NCI) 
Study terminated by sponsor An indication that a clinical study was stopped by its sponsor (NCI) 
Withdrawal by subject An indication that a study participant has removed itself from the study (NCI) 
 
Collection of Pregnancy Information: 
Female Participants Who Become Pregnant  
 The investigator will collect pregnancy information on any female participant who becomes 
pregnant while particip ating in this study. Information wi ll be recorded on  the appropriate 
form and submitted to Allergan within 24 hours of learning of a participant’s pregnancy. 
11DEC2020 CSR 1789-202-008
60

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow-up information on the participant and the neonate, and the information will be forwarded to Allergan. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy 
will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
 While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
will be reported as an AE or SAE. Abnor mal pregnancy outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) or genetic 
abnormalities (whether leading to an elective abortion or not) are always considered to be 
SAEs and will be reported as such. Any poststudy pregnancy-related SAE considered reasonably related to the study intervention by the investigator will be reported to Allergan 
as described in Section 8.3.4 . While the investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through 
spontaneous reporting.  
 If a pregnancy is confirmed after the part icipant has received study intervention, the 
participant may choose to exit the study after appropriate safety follow-up or to remain in 
the study for all safety and efficacy follow-up assessments through the end-of-study visit.   
 
11DEC2020 CSR 1789-202-008
61

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.5. Appendix 5: Study Tabular Summary 
This table is intended for use in posting study inform ation to registries (eg, ClinicalTrials.gov). 
Parameter Group Parameter Value 
Trial information Trial Title BOTOX® (onabotulinumtoxinA) 
Treatment of Masseter Muscle 
Prominence: A Phase 2b, Multicenter, 
Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study 
 Clinical Study Sponsor Allergan Sales, LLC. 
 Trial Phase Classification Phase 2b trial 
 Trial Indication Masseter Muscle Prominence 
 Trial Indication Type Treatment 
 Trial Type Efficacy 
Safety 
 Trial Length 180 days plus a 14-day screening period 
 Planned Country of Investigational Sites US  
 Planned Number of Participants 150 
 FDA-Regulated Device Study No 
 FDA-Regulated Drug Study Yes 
 Pediatric Study No 
Participant information Diagnosis Group Masseter Muscle Prominence
 
 Healthy Participant Indicator Yes 
 Planned Minimum Age of Participants 18 
 Planned Maximum Age of Participants Not specified 
 Sex of Participants Both 
 Stable Disease Minimum Duration Not specified 
11DEC2020 CSR 1789-202-008
62

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Parameter Group Parameter Value 
Treatments Investigational Therapy or Treatment OnabotulinumtoxinA 
 Intervention Type Drug 
 Pharmacological Class of Invest. Therapy Neurotoxin 
 Dose per Administration 48 or 72 
 Dose Units U 
 Dosing Frequency Single treatment 
 Route of Administration Intramuscular 
 Current Therapy or Treatment No 
 Added on to Existing Treatments No 
 Control Type Placebo  
 Comparative Treatment Name Placebo 
Trial design Study Type Interventional 
 Intervention Model Parallel 
 Planned Number of Arms 3 
 Trial is Randomized Yes 
 Randomization Quotient 1:1:1 
 Trial Blinding Schema Double blind 
 Stratification Factor Day 1 MMPS Grade (4 or 5) 
 Adaptive Design No 
 Study Stop Rules None 
 
 
11DEC2020 CSR 1789-202-008
63

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.6. Appendix 6: Contraceptive Guidan ce and Collection of Pregnancy 
Information  
Definitions: 
WOCBP 
A woman is considered fertile following mena rche and until becoming postmenopausal unless 
permanently sterile (see below). 
Women in the following categories are not considered WOCBP: 
1. Premenarchal 
2. Premenopausal female with 1 of the following: 
 Documented hysterectomy 
 Documented bilateral salpingectomy 
 Documented bilateral oophorectomy 
Note: Documentation can come from the site  personnel’s: review of the participant’s 
medical records, medical examination, or medical history interview. 
3. Postmenopausal female 
 A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormo nal contraception or HRT. However, in 
the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.  
 Females on HRT and whose menopausal status is in doubt will be required to use one of 
the nonestrogen hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwis e, they must discontinue HRT to allow 
confirmation of postmenopausal st atus before study enrollment. 
Contraception Guidance: 
Female Participants 
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective or acceptable m ethod of contracep tion consistently and corre ctly as described in 
Table 10-1 . 
 
11DEC2020 CSR 1789-202-008
64

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Table 10-1 Highly Effective and Acceptable Contraceptive Methods 
Highly Effective Contraceptive Methods That Are User Dependenta  
Failure rate of < 1% per year when used consistently and correctly   
Combined (estrogen- and progestogen-c ontaining) hormonal contraception associated with inhibition of ovulation 
 Oral  
 Intravaginal  
 Transdermal  
Progestogen-only hormonal contraception associated with  inhibition of ovulation 
 Oral  
 Injectable  
Highly Effective Methods That Are User Independenta  
 Implantable progestogen-only hormonal contraception associated with inhibition of ovulation 
 IUD 
 IUS 
 Etonogestrel implant (ie, Nexplanon®) 
 Bilateral tubal occlusion (eg. Essure, bilateral tubal ligation) 
 Intrauterine copper contraceptive (ie, ParaGard®) 
Vasectomized Partner  
A vasectomized partner is a highly effective contraception method provided that the partner is the sole male 
sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.   
Sexual Abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of 
the participant.   
Acceptable Methods   
Acceptable birth control methods that result in a failure of more than 1% per year include: 
 Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of 
action 
 Male or female condom with or without spermicide  
 Cap, diaphragm, or sponge with spermicide 
 Nonhormonal intrauterine device  
A combination of male condom with either cap, diaphragm, or sponge with spermici de (double-barrier methods) 
are also considered acceptable, but not hi ghly effective, birth control methods. 
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive methods for partic ipants participating in clinical 
studies.  
Pregnancy Testing: 
 WOCBP should only be included after a confir med menstrual period and a negative highly 
sensitive pregnancy test at screening and also a negative test on Day 1. 
 Additional pregnancy testing s hould be performed at study exit,  and as required locally. 
11DEC2020 CSR 1789-202-008
65

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 Pregnancy testing will be performed whenev er a menstrual cycle is missed or when 
pregnancy is otherwise suspected.  
 Urine pregnancy testing will be used unless the study site requires the use of serum testing, 
in which case serum testing will be used. 
11DEC2020 CSR 1789-202-008
66

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.7. Appendix 7: Efficacy Measures 
10.7.1. Masseter Muscle Prominence Scale – Investigator Assessment 
Instructions 
Using visual inspection and palpation, you will ra te the masseter muscle prominence during rest 
and function, by separately evaluating the ri ght and left side of the subject’s face. 
• Sit directly in front of the subject and inspect the contour of the face in the clenched 
and unclenched state. 
• Define the posterior and anterior border of  each masseter, as well as the superior and 
inferior margins. 
• While the subject clenches and relaxes, use your fingers to feel the dimensions and surface texture of each masseter. 
• Have the subject repeat the sequence of clen ching and relaxing at least twice. As best 
as possible, distinguish masseter muscle fr om bone and other non-muscular soft tissue 
(eg, fat). 
• Rate each masseter separately by selecting one response per masseter. In the presence 
of discordant assessment between rest and clenched states, the subject’s masseter 
prominence assessment noted in the clenched state should factor most significantly in 
determining the overall rating for each side of the face. 
11DEC2020 CSR 1789-202-008
67

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Rating Clinical Evaluation 
Minimal (1)  AT REST:  With mouth closed and no clenching, surface overlying masseter is concave.  
There is no contour contributed by masseter muscle.  Masseter is not palpable.  
AT CLENCH:  No visible difference in contou r compared with when mouth is closed, no 
clenching.  Masseter is minimally palpable and difficult to define.  
Mild (2)  AT REST:  With mouth closed and no clenching, surface overlying masseter is flat or 
slightly concave.  The contour contributed by masseter muscle may or may not be visible.  
Masseter is minimally palpable. 
AT CLENCH:  With clenching, minimal differen ce in lower facial contour compared with 
when mouth is closed, no clenching.  Portion of masseter bulk may be visible and palpable. 
Moderate (3)  AT REST:  With mouth closed and no clenching, surface overlying masseter is flat or 
convex.  The contour contributed by masseter muscle may or may not be visible.  Masseter 
is palpable. 
AT CLENCH:  With clenching, the lower face is more convex in co ntour compared with 
when mouth is closed, no clenching.  Masseter bulk is easily identifiable, palpable, and 
firm.  
Marked (4)  AT REST:  With mouth closed and no clenching, surface overlying masseter is convex.  
The masseter muscle, in conjunction with the chin and jawline, creates a square lower 
facial contour.  Masseter is palpable and firm. 
AT CLENCH:  With clenching, the lower face is wider and squarer compared with when 
mouth is closed, no clenching.  Masseter is palpable and firm or hard.  
Very Marked (5) AT REST:  With mouth closed and no clenching, surface overlying masseter is convex.  
The masseter muscle, in conjunction with the ch in and jawline, creates a trapezoidal lower 
facial contour.  Masseter is palpable and firm. 
AT CLENCH:  With clenching, the lower face is more trapezoidal compared with when 
mouth is closed, no clenching.  Masseter is palpable and hard.  
 
11DEC2020 CSR 1789-202-008
68

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.7.2. Lower Facial Volume Measurement 
The lower facial volume measurement (cm3) will be performed by , Inc using 
2 analysis methods, as described below. 
Landmark AOI Analysis Method 
To measure the difference in volume between tw o 3D surface models from different timepoints 
(ie, baseline and posttreatment), the models are first registered in 3D space such that relative 
surfaces unrelated to the treatment regions are correspondingly aligned. The analysis region is 
then defined using a series of anatomical landm arks placed on the baseline surface that are then 
projected mathematically to the posttreatment surface and verified by the analysis technician. 
In Figure 10-1 , the green-shaded region represents th e defined measurement selection area 
created by the perimeter formed using landmarks (C-F-D-E). Anatomical landmarks are located 
at: Lateral canthus (A), Alar recess (B), Earlobe attachment point (C),  Prejowl sulcus (D), 
Mandible point (E). A single interpolated landmark (F) is also used at the intersection point of 
surface lines between points (A)-(D) and (B)-(C). 
The difference in volume is then measured between the select region of the baseline surface and 
the select region of the posttr eatment surface. The lower facial volume is the summed volumes 
for both the left side and the right side of the face, which will be compared between each paired 
baseline/posttreatment timepoint for the study. 
In response to treatment, the region is  expected to decrease in volume. 
 
Figure 10-1 Lower Facial Volume Measurement 
 
11DEC2020 CSR 1789-202-008
69

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Statistical MMP AOI Analysis Method 
An additional method of lower facial volume anal ysis will be performed using a statistical MMP 
AOI model (MMP AOI) to calculate the full ar ea of change in lower facial volume ( Figure 10-2). 
The MMP AOI was developed based on a statistical  shape averaging of the area of change post 
masseter treatment from multiple facial models, which defines the mask area used for 
analysis. The MMP AOI approach allows the imag e analysis methodology to be better targeted 
to the full change contributed from the masse ter muscle on a participant-by-participant 
basis. This improved targeting also reduces the potential for non-target anatomy noise and 
variability (ie, peri-oral expression).  
To measure the difference in volume between tw o 3D surface models from different timepoints 
(ie, baseline, posttreatment) using the MMP AOI me thod, the models are also registered in 3D 
space such that relative surfaces unrelated to th e treatment regions are aligned correspondingly. 
Figure 10-2 Standardized  Target AOI from a 3D Facial Shape Model 
 
 
In conclusion, the change from baseline in lo wer facial volume for both landmark AOI (as used 
in Study 191622-130) and statisti cal MMP AOI (the new method described above) will be 
analyzed using ANCOVA with study intervention an d investigator site as factors, and baseline 
MMPS Grade as a covariate. 
10.7.3. Facial Width Measurement 
Facial width measurements (mm) will be performed by  
To m easure lower facial width, the fo llowing lines (A, B, and C) are drawn from the frontal 
facial im age. In Figure 10-3  below, Line A depicts th e width of the face at th e level of the 
stomion, the midline point at the junction of th e upper and lower lip verm illion. Line B depicts 
the alar base width. The alar base width is defi ned as the distance between the left and right alar 
rim, and not the left and right al ar crease junction. Line C depi cts the distance between the right 
and left medial canthus. Intercanthal distance (C ) and alar base width (B) are anticipated to 
remain constant during the course of the st udy and to be unaffected by study intervention. 
The width of the face (A) as well as ratio of alar base width to facial widt h (B/A) and the ratio of 
intercanthal width to facial width (C/A) will be calculated for each participant and visit. 
11DEC2020 CSR 1789-202-008
70

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 
Figure 10-3 Lower Facial Width Measurement 
 
  
C 
B 
A 
11DEC2020 CSR 1789-202-008
71

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
10.7.4. Mandibular Facial Angle Measurement 
The mandibular facial angle measurement (degrees ) will be performed by , 
Inc. 
To measure the mandibular angle, the following li nes are drawn and angle X measured from the 
frontal facial im age (see Figure 10-4 b elow). 
Line A is an oblique line drawn acr oss the contour of the horizontal part of the jawline. Line B is 
another oblique line drawn from the most lateral aspect of cheek to the angle of the mandible 
outlining the plane of the face containing the vertical ramus of the mandible. Lines A and B 
intersect at the apex of the angle of the mandibl e. Angle X is measured as the internal angle 
between the horizontal (A) and vertical (B) lines. 
The angle X will be calculated for the left side and right side of the face and averaged for each 
participant at each visit. The percent change in the averaged angle from baseline and the 
averaged angle from posttreatment will be calcu lated for each participant and each posttreatment 
visit. 
Figure 10-4 Mandibular Facial Angle Measurement 
 
 
11DEC2020 CSR 1789-202-008
72

 
 
A p pr o v al D at e :  
 1 2- F e b- 2 0 1 9 B O T O X 
1 0. 8.  
T his A p p
will pr o v
1 0. 8. 1.  
I N S T R U
W he n a n
of y o ur f
T here ar e
res p o nse 
a b o ve. A p pe n d
Descri p 
pe n di x pr o v i
vi de res p o ns e
M assete r
UC TI O N S: T
ns weri n g t hi s
face fr o m t h e
e n o ri g ht o r 
t hat best de di x 8: E x a m
ti o ns, a n d
ides c o m ple t
es i n electr o n
r M uscle Pr o
The f oll o wi n g
s q uesti o n, p 
e t o p of y o u r
wr o n g a ns w
scri bes t he smple P ati e
d I nstr ucti 
te sa m ples o 
nic ta blets ( i
omi ne nce S 
g q uesti o n i s
lease ta ke i n
r c hee ks t o y
wers. Please 
size a n d s ha pent Re p or t
o ns 
f eac h C O A 
ie, e C O A) a t
c ale – P art i
s a b o ut h o w 
nt o c o nsi der a
yo ur c hi n).  
l o o k at y o u r
pe of t he are te d O utc o
q uesti o n na i
t t he st u d y s i
ici p a nt ( M M
t he l o wer p
ati o n y o ur l o
r face i n t he 
a of y o ur fa cPr ot o c
omes Q ue s
ire; h o we ve r
ite. 
MP S- P) 
part of yo u r
ower face o n
p h ot o pr o vi d
ce s h o w n i n col 1 7 8 9- 2 0 2
sti o n n aire s
r, partici pa n t
r f ace l o o ks. 
nl y ( b ott o m h
de d. Select t
t he dia gra m2- 0 0 8 
 
s, 
ts 
half 
the  
m 
1 1 D E C 2 0 2 0 C S R 1 7 8 9- 2 0 2- 0 0 8 7 3 
 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
1 Not at all pronounced The muscles in the area do not stand out; the jawline is 
not wide. 
2 Mildly pronounced The muscles in the area stand out slightly; the jawline is 
slightly wide. 
3 Moderately pronounced The muscles in the area stand out somewhat; the jawline is somewhat wide. 

4 Pronounced The muscles in the area stand out a great deal; the jawline is very wide. 

5 Very pronounced The muscles in the area stand out extremely; the jawline is extremely wide. 
11DEC2020 CSR 1789-202-008
74

 
 
A p pr o v al D at e :  
 1 2- F e b- 2 0 1 9  
B O T O X 
G R D- C L N -1 0. 8. 2.  
I N S T R U
was ta ke n
please ta k
y o ur c he e
Please c o
C o m par e
t o da y is: 
3 
2 
1 
0 
-1
-2
-3 
-T- 0 1- 0 1 v 3. 0 M assete r
UC TI O N S:  Y
n bef ore tre a
ke i nt o c o ns 
eks t o y o ur c
om pare t he p
ed t o t he p h o
M uc h i m
M o d er a t
i m pr o v e 
Mi ni m al 
N o c h a n 
1 Mi ni m al 
2 M o d er a t
3 M uc h  w or M uscle Pr o
Yo u will be s
at me nt be ga n
i derati o n y o
chi n).   
ph ot o gra p hs 
ot o ta ke n be f
mpr o v e d 
tely 
d 
l y i m pr o v e d 
g e 
l y w ors e 
tely w ors e 
ors e omi ne nce P
sh o w n t w o p
n, a n d t he o t
ur l o wer fa c
pr o vi de d a n
fore treat me n
 
 
  
 
 
 
 Partici p a nt S
ph ot o gra p hs 
ther was ta k e
ce o nl y ( b ott o
nd select a r e
nt, t he s ha p eSelf- Assess m
of y o ur l o w
en t o da y. W h
o m half of y
es p o nse f or t h
e of t he l o w ePr ot o c
me nt of C h a
wer face.  O n
he n a ns weri 
yo ur fa ce fr o 
the f oll o wi n g
er face i n t h ecol 1 7 8 9- 2 0 2
ange ( P S A C
ne p h ot o gra p 
n g t his q ues 
om t he t o p o f
g q uesti o n . 
e p h ot o ta ke n2- 0 0 8 
 
C) 
h 
ti o n, 
f 
n 
1 1 D E C 2 0 2 0 C S R 1 7 8 9- 2 0 2- 0 0 8 7 5 
 
 
Approval Date :  
 12-Feb-2019BOTOX 
 
Proto ccol 1789-20 22-008 
 
11DEC2020 CSR 1789-202-008
76

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
11DEC2020 CSR 1789-202-008
77

 
 
Approval Date :  
 12-Feb-2019 
BOTOX  
 
Proto ccol 1789-20 22-008 
 
11DEC2020 CSR 1789-202-008
78

 
 
Approval Date :  
 12-Feb-2019 
CONFI
BOTOX  
 
Proto ccol 1789-20 22-008 
 
11DEC2020 CSR 1789-202-008
79

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
11DEC2020 CSR 1789-202-008
80

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
  
11DEC2020 CSR 1789-202-008
81

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
  
11DEC2020 CSR 1789-202-008
82

 
 
Approval Date :  
 12-Feb-2019 
BOTOX 
 
Proto ccol 1789-20 22-008 
 
11DEC2020 CSR 1789-202-008
83

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
 
11DEC2020 CSR 1789-202-008
84

 
 
Approval Date :  
 12-Feb-2019 
BOTOX  
 
Proto ccol 1789-20 22-008 
 
11DEC2020 CSR 1789-202-008
85

 
 
Approval Date :  
 12-Feb-2019 
BOTOX 
 
  
 
Proto ccol 1789-20 22-008 
 
11DEC2020 CSR 1789-202-008
86

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
11DEC2020 CSR 1789-202-008
87

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
11. References 
Adriaens J, van Loon B, Ingels KJ, Be rge SJ, Maal TJ. Three-dimensional 
stereophotogrammetric method of quantifying the eff ect of botulinum toxin type A injections on 
masseter hypertrophy. Plast Reconstr Surg. 2012;130(2):376e-378e. 
Ahn J, Horn C, Blitzer A. Botulinum toxin for ma sseter reduction in Asian patients. Arch Facial 
Plast Surg. 2004;6(3):188-191. Aydil B, Basaran B, Unsaler S, Suoglu Y . The use of botulinum toxin type A in masseteric 
muscle hypertrophy: long-term effects and lastin g improvement. Kulak Burun Boggaz Ihtis Derg 
(Journal of Ear, Nose and Throat). 2012;22(5) :249-253. [English translation from Turkish] 
Baek SM, Kim SS, Bindiger A. The prominent mandibular angle: preoperative management, 
operative technique, and results in 42 pa tients. Plast Reconstr Surg. 1989;83:272-278. 
Chai G, Zhang Y , Zhu M, Ma X, Yu Z, Mu X, Qi Z. Evaluation of dynamic morphologic changes 
in the masseter muscle in patients undergoing mandibular angle sagittal split osteotomy. Arch 
Facial Plast Surg. 2011;13:301-304. 
Chang CS, Kang G C-W. Achieving ideal lowe r face aesthetic contours: combination of 
tridimensional fat grafting to the chin with masseter botulinum toxin injection. Aesthetic Surgery 
Journal, 2016;36(10):1093–1100. 
Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the 
lower face. Dermatol Surg. 2005;31(5):502-508. de Menezes M, Rosati R, Ferrario VF, Sforza C. Accuracy and reproducibili ty of a 3-dimensional 
stereophotogrammetric imaging system. J Oral Maxillofac Surg. 2010;68:2129-2135. 
Deguchi M, Iio Y , Kobayashi K, Shirakabe T. Angle-splitting ostectomy for reducing the width 
of the lower face. Plast Reconstr Surg. 1997;99:1831-1839. Fedorowicz Z, van Zuuren EJ, Schoones J. Botu linum toxin for masseter hypertrophy.  Cochrane 
Database Syst Rev. 2013;(9):CD007510. Review. Herrero BA, Ecklung AE, Streett CS, Ford DF, King JK. Experimental botulism in monkeys: a 
clinical pathological study. Exp Mol Pathol. 1967;6:84-95. 
11DEC2020 CSR 1789-202-008
88

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Hong HS, Kang SC, Kim C-Y , Kim ST. Long-term evaluation of the effect of botulinum toxin A 
injection in patients with masseteric hypertr ophy. Korean J Oral Med. 2005;30(1):121-129. 
Jin H. Misconceptions about mandible redu ction procedures. Aesthetic Plast Surg. 
2005;29:317-324. 
Jin H, Kim BG. Mandible reduction versus mandi bular angle reduction. Plast Reconstr Surg. 
2004;114:1263-1269. Kim HJ, Yum K-W, Lee S-S, Heo M-S, Seo K. Ef fects of botulinum toxin type A on bilateral 
masseteric hypertrophy evaluated with computed  tomographic measurement. Dermatol Surg. 
2003;29:484-489. Kim J-H, Shin JH, Kim ST, Kim C-Y . Effects of two different units of botulinum toxin type A 
evaluated by computed tomography and elec tromyographic measurement of human masseter 
muscle. Plast Reconstr Surg. 2007;119(2):711-717. 
Kim N-H, Chung J-H, Park R-H, Park J-B. The use of botulinum toxin type A in aesthetic 
mandibular contouring. Plast Reco nstr Surg. 2005;115(3):919-930. 
Kim SK, Han JJ, Kim JT. Classifi cation and treatment of prominen t mandibular angle. Aesthetic 
Plast Surg. 2001;25:382–387. Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA. Lower facial remodeling with 
botulinum toxin type A for the treatment of  masseter hypertrophy. An Bras Dermatol. 
2014;89:878-884. 
Lee JG, Park YW. Intraoral approach for reducti on malarplasty: a simple method. Plast Reconstr 
Surg. 2003;111:453-460. Lee KC, Ha SU, Park JM, Kim SK, Park SH, Kim JH. Reduction malarplasty by 3-mm 
percutaneous osteotomy. Aesthetic Plast Surg. 2006;30:333–341. Liew S, Dart A. Nonsurgical reshaping of the lower face. Aesthet Surg J. 2008;28(3):251-257. 
Mischkowski RA, Siessegger M, Lazar F, Zoller JE . [Chemodenervation with botulinum toxin in 
masseteric hypertrophy]. Mund-, Kiefer-und Gesichtschir. 200 5;9(2):101-108. 
11DEC2020 CSR 1789-202-008
89

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Moore AP, Wood GD. The medical management of  masseter hypertrophy with botulinum toxin 
type A. Br J Oral Maxillofac Surg. 1994;32(1):26-28. 
Morris DE, Moaveni Z, Lo L-J. Aesthetic facial skeletal contouring in the Asian patient. Clin 
Plastic Surg. 2007;34:547–556. Mu X. Experience in East Asian facial re contouring: reduction mala rplasty and mandibular 
reshaping. Arch Facial Plast Surg. 2010;12:222-229. Onizuka T, Watanabe K, Takasu K, Keyama A. Reduction malar plasty. Aesthetic Plast Surg. 
1983;7:121-125. 
Park MY , Ahn KY , Jung DS. Botulinum toxin type  A treatment for contouring of the lower face. 
Dermatol Surg. 2003;29:477-483. Park YJ, Jo YW, Bang SI, Kim HJ, Lim SY , Mun GH, et al. Radiofrequency volumetric 
reduction for masseteric hypertrophy. Ae sthetic Plast Surg. 2007;31:42-52. 
Peng H-L P, Peng J-H. Complications of botu linum toxin injection for masseter hypertrophy: 
incidence rate from 2036 treatments and summar y of causes and preventions. J Cosmet Dermatol. 
2017;00:1-6. 
Pu Z, Zhang Y , Yang J, Liu T, Zhang Y , Yang Q, et al. Mandibular angle ostectomy for Chinese 
women: approaches and extent determined by cephalometric analysis. J Craniofac Surg. 
2009;20:105-110. 
Rauso R, Santagata M, Colella G. Can occlusal devices prolong the effect of botulinum toxin 
type A in the contouring of the lowe r face? Eur J Plast Surg. 2010;33:35-40. 
Scott AB. Clostridial toxins as therapeutic agen ts. In: Simpson LL, editor. Botulinum neurotoxin 
and tetanus toxin. New York, Academic Press. 1989;399-412. 
Shim WH, Yoon SH, Park JH, Choi Y-C, Kim ST. Effect of botulinum toxin type A injection on 
lower facial contouring evaluated using a th ree-dimensional laser scan. Dermatol Surg. 
2010;36(Suppl 4):2161-2166. 
Smyth AG. Botulinum toxin treatment of bilate ral masseteric hypertrophy. Br J Oral Maxillofac 
Surg. 1994;32:29-33. 
11DEC2020 CSR 1789-202-008
90

 
 
Approval Date :  
 12-Feb-2019 
 Protocol 1789-202-008 
BOTOX  
 
Sumiya N, Yoshinori I, Ozumi K. Reduc tion malarplasty. Plast Reconstr Surg. 
2004;113:1497-1499. 
Tartaro G, Rauso R, Santagata M, Santillo V , Itro A. Lower facial contouring with botulinum 
toxin type A. J Craniofac Surg. 2008;19:1613-1617.  To EWH, Ahuja AT, Ho WS, King WWK, Wong WK , Pang PCW, et al. A prospective study of 
the effect of botulinum toxin A on masseteri c muscle hypertrophy with  ultrasonographic and 
electromyographic measurement. Br J Plast Surg. 2001;54:197-200. 
Tzou C-H J, Frey M. Evolution of 3D surface imag ing systems in facial plastic surgery. Facial 
Plast Surg Clin North Am. 2011;19:591-602. 
Wu WTL. Botox facial slimming/fa cial sculpting: the role of botulinum toxin-A in the treatment 
of hypertrophic masseter muscle and parotid en largement to narrow the lower facial width. 
Facial Plastic Surgery Clinics of  North America 2010;18(1):133-140. 
Xie Y , Zhou J, Li H, Cheng C, Herrler T, Li  Q. Classification of Masseter Hypertrophy for 
Tailored Botulinum Toxin Type A Treatment. Plast Reconstr Surg. 2014;134:209e-218e. 
Yang DB, Park CG. Mandibular contouring surgery for purely aesthetic reasons. Aesthetic Plast 
Surg. 1991;15:53–60. Yang DB, Song HS, Park CG. Unfavorable results and their resolution in mandibular contouring 
surgery. Aesthetic Plast Surg. 1995;19:93-102. 
 
11DEC2020 CSR 1789-202-008
91

 
 
Approval Date :  
 12-Feb-2019ALLERGAN  
 
 
 
 
    
 
Date (DD/MMM/YYYY)/Time (PT)  Signed by:  Justification  
    
                         
                         
                         
                  
                         
                         
                         
                         
                         
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
 Protocol 1789-202-008
11DEC2020 CSR 1789-202-008
92
